<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004257252
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Talvey
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TALQUETAMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24417.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Talvey is a cancer medicine that contains the active substance talquetamab. Talquetamab is an antibody, a type of protein that recognises and attaches to specific targets in your body. It has been designed to attach to the protien GPRC5D (G Protein‑coupled receptor family C group 5 member D), which is found on multiple myeloma cancer cells, and to CD3, a protein on T cells (a type of white blood cell). T cells are a part of the body&rsquo;s natural defences and help protect the body from infection. They can also destroy cancer cells. When this medicine attaches to these cells, it brings the cancer cells and T cells together. This encourages the T cells to destroy the multiple myeloma cancer cells.</p><p>&nbsp;</p><p>Talvey is used to treat adults with multiple myeloma, a cancer of the bone marrow.</p><p>It is used when patients have had at least three other types of treatment that have not worked or have stopped working.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Talvey</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to talquetamab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p>Do not use Talvey if the above applies to you. If you are not sure, talk to your doctor or nurse before you are given Talvey.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or nurse before you are given Talvey.</p><p>&nbsp;</p><p><u>Serious side effects</u></p><p>There are serious side effects that may occur after you start taking Talvey. You need to tell your doctor or nurse straight away if these occur, as they may require that you get immediate medical attention.</p><p>&nbsp;</p><p><strong>Tell your doctor or nurse right away if you experience any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of a condition known as &lsquo;cytokine release syndrome&rsquo; (CRS). CRS is a serious immune reaction with symptoms such as fever, low blood pressure, chills, difficulty breathing, fatigue, headache, fast heart beat and increased level of liver enzymes in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on your nervous system. Symptoms include feeling confused, feeling disoriented, feeling sleepy, feeling less alert, slow or difficulty thinking, altered thinking or decreased conciousness, confusion, difficulty speaking and understanding speech. Some of these may be signs of a serious immune reaction called &lsquo;immune effector cell‑associated neurotoxicity syndrome&rsquo; (ICANS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with the mouth, such as a loss of taste, dry mouth, difficulty swallowing and inflammation of the lining of the mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems such as rash, redness and nail problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling warm, fever, chills or shivering, sore throat or mouth ulcers may be signs of an infection.</p><p>&nbsp;</p><p><u>Talvey and vaccines</u></p><p>Talk to your doctor or nurse before you are given Talvey if you have had a recent vaccination or are going to have a vaccination. Your immune system (the body&rsquo;s natural defences) may not respond as well to vaccination when you are taking this medicine.</p><p>&nbsp;</p><p>You should not receive live vaccines, a specific type of vaccine, from at least 4 weeks before starting your treatment with Talvey until at least 4 weeks after you have taken your last dose.</p><p>&nbsp;</p><p><u>Tests and checks</u></p><p><strong>Before </strong>you are given Talvey your doctor will check your blood to look at the levels of different blood cells and to test for signs of infection. Infections will be treated before you start taking this medicine.</p><p><strong>After</strong> you have Talvey your doctor will monitor you for side effects. They will also regularly check your blood counts, as the number of blood cells and other blood components may decrease when you use this medicine.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Talvey should not be used in children or young people below 18&nbsp;years of age, because the medicine has not been studied in this age group and it is not known how this medicine will affect them.</p><p>&nbsp;</p><p><strong>Other medicines and Talvey</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. This includes medicines you can get without a prescription and herbal medicines.</p><p>&nbsp;</p><p><strong>Pregnancy, contraception and breast-feeding</strong></p><p><u>&nbsp;</u></p><p><u>Pregnancy and contraception</u></p><p>Talvey has the potential to be transmitted from the mother to the developing foetus. The effects of Talvey on the developing foetus are unknown and a risk to newborns/infants cannot be excluded.</p><p>&nbsp;</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before you are given this medicine.</p><p>If you become pregnant while being treated with this medicine, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you could become pregnant, you must use effective contraception during treatment and for 3&nbsp;months after stopping treatment with Talvey. Your doctor will check if you are pregnant before starting treatment.</p><p>&nbsp;</p><p>If your partner becomes pregnant while you are taking this medicine, tell your doctor straight away.</p><p>&nbsp;</p><p>If you have taken this medicine during pregnancy, your newborn baby should not be given any live vaccines until he or she is at least four&nbsp;weeks old.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>It is not known if Talvey passes into breast milk. There may be a risk to breastfed newborns/infants. Ask your doctor for advice before starting this medicine. You and your doctor will decide if the benefit of breast‑feeding is greater than the risk to your baby. If you and your doctor decide to stop taking this medicine, you should not breast‑feed for 3 months after stopping treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Some people may feel tired, dizzy, or confused while taking Talvey. Do not drive, use tools or machines from recieving your first dose until at least 48&nbsp;hours after receiving your first treatment dose of Talvey or as instructed by your doctor.</p><p>&nbsp;</p><p><strong>Talvey contains sodium</strong></p><p>Talvey contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>Talvey will be given to you under supervision by a doctor experienced in treating patients with multiple myeloma. Your doctor will decide how much Talvey you are given. The dose of Talvey will depend on your body weight.</p><p>&nbsp;</p><p>Talvey is given either once a week or once every 2&nbsp;weeks, depending on the dose, as follows:</p><p>&nbsp;</p><p><u>0.4&nbsp;mg/kg once a week:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your first dose, you will receive 0.01&nbsp;mg per kilogram of bodyweight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your second dose, which will be given 2-4&nbsp;days later, you will receive 0.06&nbsp;mg per kilogram of bodyweight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your third dose, you will receive a &lsquo;Treatment dose&rsquo; of 0.4&nbsp;mg per kilogram of bodyweight 2-4&nbsp;days after your second dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After your third dose, you will then receive a &lsquo;Treatment dose&rsquo; once a week thereafter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment will continue for as long as you benefit from having Talvey.</p><p>&nbsp;</p><p>Your doctor will monitor you for side effects after each of your first three doses. They will do this for 2 days after each dose. You should stay close to a healthcare facility after each of the first three doses in case you have side effects.</p><p>&nbsp;</p><p>If you experience side effects after any of your first two doses, your doctor may decide to wait up to 7 days before giving you your next dose.</p><p>&nbsp;</p><p><u>0.8&nbsp;mg/kg once every 2&nbsp;weeks:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your first dose, you will receive 0.01&nbsp;mg for each kilogram of bodyweight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your second dose, which will be given 2‑4&nbsp;days later, you will receive 0.06&nbsp;mg per kilogram of bodyweight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your third dose, which will be given 2‑4&nbsp;days later, you will receive 0.4&nbsp;mg per kilogram of bodyweight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your fourth dose, you will then receive a &lsquo;Treatment dose&rsquo; of 0.8&nbsp;mg per kilogram of bodyweight 2‑4&nbsp;days after your third dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After your fourth dose, you will then receive a &lsquo;Treatment dose&rsquo; once every 2&nbsp;weeks thereafter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment will continue for as long as you benefit from having Talvey.</p><p>&nbsp;</p><p>Your doctor will monitor you for side effects after each of your first four doses. They will do this for 2&nbsp;days after each dose. You should stay close to a healthcare facility after each of the first four doses &nbsp;in case you have side effects.</p><p>&nbsp;</p><p>If you experience side effects after any of your first three doses, your doctor may decide to wait up to 7 days before giving you your next dose.</p><p>&nbsp;</p><p>The decision to use either the 0.4&nbsp;mg/kg once weekly or 0.8&nbsp;mg/kg every two weeks should be made in consultation with your doctor.</p><p>&nbsp;</p><p><strong>How the medicine is given</strong></p><p>Talvey will be given to you by a doctor or nurse as an injection under your skin (&lsquo;subcutaneous&rsquo; injection). It is given in the stomach area (abdomen) or thigh.</p><p>&nbsp;</p><p><strong>Medicines given during treatment with Talvey</strong></p><p>Before the first three doses (if you are given 0.4&nbsp;mg/kg bodyweight) or the first four doses (if you are given 0.8&nbsp;mg/kg bodyweight) of Talvey, you will be given medicines which help to lower the chance of side effects. These may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce an allergic reaction (antihistamines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce inflammation (corticosteroids)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce fever (such as paracetamol)</p><p>&nbsp;</p><p>You may also be given these medicines for when you take later doses of Talvey based on any symptoms you have.</p><p>&nbsp;</p><p>You may also be given additional medicines based on any symptoms you experience or your medical history.</p><p>&nbsp;</p><p><strong>If you are given more Talvey than you should</strong></p><p>This medicine will be given by your doctor or nurse. In the event that you are given too much (an overdose) your doctor will check you for side effects.</p><p>&nbsp;</p><p><strong>If you forget your appointment to have Talvey</strong></p><p>It is very important to go to all your appointments to make sure your treatment works. If you miss an appointment, make another one as soon as possible.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong><u>Serious side effects</u></strong></p><p>Get medical help straight away if you get any of the following serious side effects which may be severe and can be fatal.</p><p>&nbsp;</p><p><strong>Very Common (may affect more than 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune effector cell-associated neurotoxicity syndrome (ICANS), a serious immune reaction that may affect your nervous system. Some of the symptoms are:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being less alert or aware</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling disoriented</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low energy</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow and difficulty thinking.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytokine release syndrome (CRS), a serious immune reaction. CRS may cause symptoms such as:</p><p>o&nbsp;&nbsp; fever</p><p>o&nbsp;&nbsp; low blood pressure</p><p>o&nbsp;&nbsp; chills</p><p>o&nbsp;&nbsp; low level of oxygen in the blood</p><p>o&nbsp;&nbsp; headache</p><p>o&nbsp;&nbsp; fast heart beat</p><p>o&nbsp;&nbsp; increased level of liver enzymes in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of neutrophils (neutropenia), a type of white blood cell that helps fight infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of blood platelets (thrombocytopenia), which help blood to clot</p><p>&nbsp;</p><p>Tell your doctor right away if you notice any of the above listed serious side effects.</p><p>&nbsp;</p><p><strong><u>Other side effects</u></strong></p><p>Other side effects are listed below. Tell your doctor or nurse if you get any of these side effects.</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nail problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the muscles and bones (musculoskeletal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally dry skin or membranes such as the mouth and eyes (xerosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of lymphocytes (lymphopenia), a type of white blood cell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problem being able to produce or control movement (motor dysfunction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage that may cause tingling, numbness, pain or loss of pain sensation (sensory neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage or disease affecting brain function (encephalopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infected nose, sinuses or throat (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells (leukopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of potassium in the blood (hypokalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of phosphate in the blood (hypophosphataemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of magnesium in the blood (hypomagnesaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of immunoglobulins, a type of antibody in the blood (hypogammaglobulinaemia), which may make infections more likely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid build up in the body (oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation or pain where the injection is given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of liver enzymes in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COVID‑19 infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show it takes longer for blood to clot (fibrinogen decreased, INR increased and PTT prolongation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath (dyspnea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with the mouth and swallowing, such as change in sense of taste (dysgeusia), dry mouth, difficulty swallowing (dysphagia), and inflammation of the lining of the mouth (stomatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems, including skin rash</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding, which can be severe (haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the lungs (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood poisoning (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of a type of white blood cell (neutrophils), with a fever</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Talvey will be stored at the hospital or clinic by your doctor. The following information is therefore mainly intended for healthcare professionals.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>Before using the medicine, check the solution for particles or discolouration. The solution should be colourless to light yellow. Do not use this medicine if it is cloudy, discoloured, or contains visible particles.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Talvey contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is talquetamab. Talvey comes in two different strengths:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;mg/mL &ndash; one 1.5&nbsp;mL vial contains 3&nbsp;mg talquetamab</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40&nbsp;mg/mL &ndash; one 1&nbsp;mL vial contains 40&nbsp;mg talquetamab</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are EDTA disodium salt dihydrate, glacial acetic acid, polysorbate 20, sodium acetate trihydrate, sucrose, water for injection (see &ldquo;Talvey contains sodium&rdquo; in section&nbsp;2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Talvey looks like and contents of the pack
	Talvey is a solution for injection (injection) and is a colourless to light yellow liquid.
	Talvey is supplied as a carton pack containing 1 glass vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen‑Cilag International NV</p><p>Turnhoutseweg 30</p><p>B‑2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>&nbsp;</p><p>Patheon Manufacturing Services LLC</p><p>5900 Martin Luther King Jr. Hwy</p><p>Greenville, NC 27834</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	To contact us , please visit our website  www.janssen.com/contact-us  

	This leaflet was last revised in August 2023. 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تالفي هو دواء للسرطان يحتوي على المادة الفعالة تالكيتاماب. تالكيتاماب هو جسم مضاد، وهو نوع من البروتين يتعرف على أهداف محددة في جسمك ويرتبط بها. وقد تم تصميمه ليرتبط بالبروتين GPRC5D (المستقبل المقترن بالبروتين G العائلة C المجموعة 5 العضو D) الذي يوجد في خلايا المايلوما المتعددة السرطانية، وCD3 (عنقود التمايز 3)، وهو بروتين على الخلايا التائية (نوع من خلايا الدم البيضاء). حيث إن الخلايا التائية هي جزء من دفاعات الجسم الطبيعية وتساعد على حماية الجسم من العدوى. ويمكنها كذلك تدمير الخلايا السرطانية. وعندما يرتبط هذا الدواء بهذه الخلايا، يجمع الخلايا السرطانية والخلايا التائية معًا. ذلك يشجع الخلايا التائية على تدمير خلايا المايلوما المتعددة السرطانية.</p><p>&nbsp;</p><p dir="RTL">يُستخدم تالفي لعلاج البالغين المصابين بالمايلوما المتعددة، وهو سرطان في نخاع العظام.</p><p dir="RTL">يُستخدم عند تلقي المرضى ثلاثة أنواع أخرى على الأقل من العلاج ولم تنجح أو توقفت عن العمل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب أن تتلقى تالفي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية من تالكيتاماب أو أي من مكونات هذا الدواء الأخرى (المدرجة في القسم&nbsp;6).</p><p>&nbsp;</p><p dir="RTL">لا تستخدم تالفي إذا كان ما ورد أعلاه ينطبق عليك. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو ممرضتك قبل أن تتلقى تالفي.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو ممرضتك قبل أن تتلقى تالفي.</p><p>&nbsp;</p><p dir="RTL"><u>الأعراض الجانبية الخطيرة</u></p><p dir="RTL">هناك أعراض جانبية خطيرة قد تحدث بعد البدء في تلقي تالفي. يلزم إبلاغ طبيبك أو ممرضتك على الفور في حالة حدوثها، حيث قد تتطلب منك تلقي عناية طبية فورية.</p><p>&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو ممرضتك على الفور إذا واجهت أيًا مما يأتي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظھور علامات تعرف باسم &quot;متلازمة إفراز السیتوكین&quot; (CRS). متلازمة إفراز السیتوكین هو رد فعل مناعي خطير مع أعراض مثل الحمى وانخفاض ضغط الدم والقشعريرة وصعوبة التنفس والتعب والصداع وسرعة ضربات القلب وزيادة مستوى إنزيمات الكبد في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات في جهازك العصبي. حيث تشمل الأعراض الشعور بالارتباك، الشعور بالتوهان، الشعور بالنعاس، الشعور بنقص الانتباه، بطء أو صعوبة في التفكير، تغير التفكير أو انخفاض الإدراك، الارتباك، صعوبة التحدث وفهم الكلام. قد تكون بعض هذه الأعراض علامات على رد فعل مناعي خطير يسمى &quot;متلازمة السمية العصبية المرتبطة بالخلايا المناعية&quot; (ICANS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الفم، مثل فقدان حاسة التذوق وجفاف الفم وصعوبة البلع والتهاب بطانة الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات جلدية مثل الطفح الجلدي والاحمرار ومشكلات في الأظافر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون الشعور بالدفء أو الحمى أو القشعريرة أو الارتعاش أو التهاب الحلق أو تقرحات الفم علامات على وجود عدوى.</p><p>&nbsp;</p><p dir="RTL"><u>تالفي واللقاحات</u></p><p dir="RTL">تحدث إلى طبيبك أو ممرضتك قبل أن تتلقى تالفي إذا كنت قد تلقيت تطعيمًا مؤخرًا أو ستتلقى تطعيمًا. قد لا يستجيب جهازك المناعي (دفاعات الجسم الطبيعية) للتطعيم بشكل جيد عند تلقيك هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">يجب ألا تتلقى لقاحات حية، وهو نوع معين من اللقاحات، من 4 أسابيع على الأقل قبل بدء علاجك باستخدام تالفي حتى بعد 4 أسابيع على الأقل من تلقيك جرعتك الأخيرة.</p><p>&nbsp;</p><p dir="RTL"><u>الاختبارات والفحوصات</u></p><p dir="RTL"><strong>قبل </strong>أن تتلقى تالفي سيقوم طبيبك بفحص دمك لمعرفة مستويات خلايا الدم المختلفة وإجراء فحص بحثًا عن علامات العدوى. سيتم علاج العدوى قبل البدء في تلقي هذا الدواء.</p><p dir="RTL"><strong>بعد</strong> تلقي تالفي سيقوم طبيبك بمراقبتك بحثًا عن الأعراض الجانبية. كما أنه سيتحقق بانتظام من تعداد الدم، حيث قد ينخفض عدد خلايا الدم ومكونات الدم الأخرى عند استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب ألا يُستخدم تالفي للأطفال والمراهقين الذين دون سن&nbsp;18 عامًا حيث لم تتم دراسة هذا الدواء لهذه الفئة العمرية وليس معروفًا ما إذا كان سيؤثر فيهم.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتالفي</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك إذا كنت تتناول أي أدوية أخرى أو تناولتها مؤخرًا أو قد تتناولها. وهذا يشمل الأدوية التي يمكنك الحصول عليها من دون وصفة طبية والأدوية العشبية.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل ومنع الحمل والرضاعة</strong></p><p><u>&nbsp;</u></p><p dir="RTL"><u>الحمل ومنع الحمل</u></p><p dir="RTL">لدى تالفي القدرة على الانتقال من الأم إلى الجنين النامي. آثار تالفي في الجنين النامي غير معروفة ولا يمكن استبعاد الخطر على الأطفال حديثي الولادة/الرُضَّع.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاستشيري طبيبك أو ممرضتك قبل تلقي هذا الدواء.</p><p dir="RTL">إذا أصبحتِ حاملاً في أثناء علاجك بهذا الدواء، فأخبري طبيبك أو ممرضتك على الفور.</p><p>&nbsp;</p><p dir="RTL">إذا كان بإمكانك الحمل، فيجب عليك استخدام وسائل منع الحمل الفعالة في أثناء العلاج ولمدة 3 أشهر بعد التوقف عن العلاج باستخدام تالفي. سيتحقق طبيبك مما إذا كنتِ حاملاً قبل بدء العلاج.</p><p>&nbsp;</p><p dir="RTL">إذا أصبحت زوجتك حاملاً في أثناء تلقيك هذا الدواء، فأخبر طبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ قد تلقيتِ هذا الدواء في أثناء الحمل، فيجب ألا يتلقى طفلك حديث الولادة أي لقاحات حية حتى يبلغ من العمر أربعة&nbsp;أسابيع على الأقل.</p><p>&nbsp;</p><p dir="RTL"><u>الرضاعة</u></p><p dir="RTL">من غير المعروف ما إذا كان تالفي ينتقل إلى حليب الثدي. قد يكون هناك خطر على الأطفال الرُضَّع/حديثي الولادة الذين يرضعون. استشيري طبيبك قبل البدء في هذا الدواء. ستقررين أنت وطبيبك ما إذا كانت فائدة الرضاعة أكبر من الخطر على طفلك. إذا قررتِ أنت وطبيبك التوقف عن تلقي هذا الدواء، فيجب ألا تُرضعي لمدة 3 أشهر بعد التوقف عن العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يشعر بعض الناس بالتعب أو الدوار أو الارتباك خلال تلقي تالفي. لا تقم بالقيادة أو استخدام الأدوات أو الآلات خلال &nbsp;48ساعة على الأقل بعد تلقي جرعة العلاج الأولى من تالفي أو وفقَ تعليمات الطبيب.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي تالفي على الصوديوم</strong></p><p dir="RTL">يحتوي تالفي على أقل من 1&nbsp;ملِّيمول من الصوديوم (&nbsp;23مجم) لكل جرعة، أي أنه يعد &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المقدار المُعطى</strong></p><p dir="RTL">سيتم إعطاؤك تالفي تحت إشراف طبيب خبير في علاج المرضى الذين يعانون من المايلوما المتعددة. سيقرر طبيبك مقدار تالفي الذي يُعطى لك. ستعتمد جرعة تالفي على وزن جسمك.</p><p>&nbsp;</p><p dir="RTL">يُعطى تالفي إما مرة واحدة في الأسبوع أو مرة واحدة كل أسبوعين، بناءً على الجرعة، على النحو الآتي:</p><p>&nbsp;</p><p dir="RTL"><u>&nbsp;0.4</u><u>مجم/كجم مرة واحدة في الأسبوع:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الأولى، ستتلقى 0.01&nbsp;مجم لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الثانية، التي سيتم إعطاؤها بعد 2-4 أيام، ستتلقى 0.06&nbsp;مجم لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الثالثة، ستتلقى &quot;جرعة علاج&quot; تبلغ 0.4&nbsp;مجم لكل كيلوجرام من وزن الجسم بعد 2-4 أيام من جرعتك الثانية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد جرعتك الثالثة، ستتلقى &quot;جرعة علاج&quot; مرة واحدة في الأسبوع بعد ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيستمر العلاج طالما أنك تستفيد من تلقي تالفي.</p><p>&nbsp;</p><p dir="RTL">سيراقبك طبيبك بحثًا عن الأعراض الجانبية بعد كل جرعة من جرعاتك الثلاث الأولى. سيفعل ذلك مدةَ يومين بعد كل جرعة. يجب أن تبقى بالقرب من منشأة رعاية صحية بعد كل جرعة من الجرعات الثلاث الأولى في حال كانت لديك أعراض جانبية.</p><p>&nbsp;</p><p dir="RTL">إذا واجهت أعراضًا جانبية بعد أي من الجرعتين الأوليين، فقد يقرر طبيبك الانتظار مدةً تصل إلى 7 أيام قبل إعطائك جرعتك التالية.</p><p>&nbsp;</p><p dir="RTL"><u>0.8</u><u>&nbsp;</u><u>مجم/كجم مرة واحدة كل&nbsp;أسبوعين:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الأولى، ستتلقى 0.01&nbsp;مجم لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الثانية، التي سيتم إعطاؤها بعد 2-4 أيام، ستتلقى 0.06&nbsp;مجم لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الثالثة، التي سيتم إعطاؤها بعد 2-4 أيام، ستتلقى 0.4&nbsp;مجم لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى جرعتك الرابعة، ستتلقى &quot;جرعة علاج&quot; تبلغ 0.8 مجم لكل كيلوجرام من وزن الجسم بعد 2-4 أيام من جرعتك الثالثة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد جرعتك الرابعة، ستتلقى &quot;جرعة علاج&quot; مرة واحدة كل&nbsp;أسبوعين بعد ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيستمر العلاج طالما أنك تستفيد من تلقي تالفي.</p><p>&nbsp;</p><p dir="RTL">سيراقبك طبيبك بحثًا عن الأعراض الجانبية بعد كل جرعة من جرعاتك الأربع الأولى. سيفعلون ذلك لمدة يومين بعد كل جرعة. يجب أن تبقى بالقرب من منشأة رعاية صحية بعد كل جرعة من الجرعات الأربع الأولى في حال كان لديك أعراض جانبية.</p><p>&nbsp;</p><p dir="RTL">إذا واجهت أعراضًا جانبية بعد أي من الثلاث جرعات الأولى، فقد يقرر طبيبك الانتظار مدةً تصل إلى 7 أيام قبل إعطائك جرعتك التالية.</p><p>&nbsp;</p><p dir="RTL">يجب اتخاذ قرار إما باستخدام 0.4 مجم/كجم مرة واحدة أسبوعيًا أو 0.8 مجم/كجم كل أسبوعين بالتشاور مع طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة إعطاء الدواء</strong></p><p dir="RTL">سيتم إعطاؤك تالفي من قِبَل طبيب أو ممرضة كحقنة تحت جلدك (حقن &quot;تحت الجلد&quot;). يُعطى في منطقة المعدة (البطن) أو الفخذ.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية المُعطاة خلال العلاج باستخدام تالفي</strong></p><p dir="RTL">قبل الجرعات الثلاث الأولى (إذا تم إعطاؤك 0.4&nbsp;مجم/كجم من وزن الجسم) أو الجرعات الأربع الأولى (إذا تم إعطاؤك 0.8&nbsp;مجم/كجم من وزن الجسم) من تالفي، فسيتم إعطاؤك الأدوية التي تساعد على تقليل احتمالية حدوث أعراض جانبية. حيث قد تشمل الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للحد من رد الفعل التحسسي (مضادات الهيستامين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للحد من الالتهاب (الستيرويدات القشرية (corticosteroids))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للحد من الحمى (مثل الباراسيتامول)</p><p>&nbsp;</p><p dir="RTL">قد تُعطى كذلك هذه الأدوية عند تلقي جرعات لاحقة من تالفي بناءً على أي أعراض لديك.</p><p>&nbsp;</p><p dir="RTL">قد تُعطى كذلك أدوية إضافية بناءً على أي أعراض تواجهها أو بناءً على تاريخك الطبي.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك تالفي أكثر مما ينبغي</strong></p><p dir="RTL">سيتم إعطاء هذا الدواء بواسطة طبيبك أو ممرضتك. في حال تم إعطاؤك الكثير (جرعة زائدة)، سيقوم طبيبك بفحصك بحثًا عن أعراض جانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت موعدك لتلقي تالفي</strong></p><p dir="RTL">من المهم جدًا الذهاب إلى جميع مواعيدك للتأكد من نجاح علاجك. إذا فاتك موعد، فحدد موعدًا آخر في أقرب وقت ممكن.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو ممرضتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من عدم حدوثها للجميع.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الأعراض الجانبية الخطيرة</u></strong></p><p dir="RTL">اطلب المساعدة الطبية مباشرة إذا كنت تعاني من أي من الأعراض الجانبية الخطيرة الآتية والتي قد تكون شديدة ويمكن أن تكون قاتلة.</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض شائعة جدًا (قد تظهر لدى أكثر من 1 من كل 10</strong><strong>&nbsp;</strong><strong>أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة السمية العصبية المرتبطة بالخلايا المناعية (ICANS)، وهي رد فعل مناعي خطير قد يؤثر في جهازك العصبي. وتشتمل بعض الأعراض على:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالارتباك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الانتباه أو الوعي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوهان</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الطاقة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء وصعوبة في التفكير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة إفراز السيتوكين (CRS)، رد فعل مناعي خطير. قد يسبب CRS أعراضًا مثل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأكسجين في الدم</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات العدلات (قلة العدلات)، وهي نوع من خلايا الدم البيضاء التي تساعد على مكافحة العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية (قلة الصفيحات) التي تساعد الدم على التجلط</p><p>&nbsp;</p><p dir="RTL">أبلغ طبيبك على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة المذكورة أعلاه.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الأعراض الجانبية الأخرى</u></strong></p><p dir="RTL">تم إدراج الأعراض الجانبية الأخرى أدناه. أخبر طبيبك أو ممرضتك إذا واجهت أيًا من هذه الأعراض الجانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض شائعة جدًا (قد تظهر لدى أكثر من 1 من كل 10</strong><strong>&nbsp;</strong><strong>أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الأظافر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والعظام (ألم عضلي هيكلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد أو الأغشية بشكل غير طبيعي مثل الفم والعينين (الجفاف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد اللمفاويات (قلة اللمفاويات)، وهي نوع من خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في القدرة على الحركة أو التحكم فيها (خلل وظيفي في الحركة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب الذي قد يسبب وخزًا أو تنميلاً أو ألمًا أو فقدان الإحساس بالألم (الاعتلال العصبي الحسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف أو مرض يؤثر في وظائف المخ (اعتلال الدماغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف أو الجيوب الأنفية أو الحلق (عدوى الجهاز التنفسي العلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (قلة الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم في الدم (نقص بوتاسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الفوسفات في الدم (نقص فوسفات الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات المغنيسيوم في الدم (نقص مغنيسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الغلوبيولين المناعي، وهو نوع من الأجسام المضادة في الدم (نقص جاما غلوبولين الدم)، ما قد يجعل العدوى أكثر احتمالاً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الناجم عن تراكم السوائل في الجسم (الوذمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج أو ألم مكان الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى كوفيد-19</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تظهر فحوصات الدم أن تجلط الدم يستغرق وقتًا أطول (انخفاض الفيبرينوجين وزيادة النسبة المعيارية الدولية (INR) وإطالة الزمن الثرومبوبلاستين الجزئي (PTT))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الفطريات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (سخونة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس (ضيق التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الفم والبلع، مثل تغير في حاسة التذوق (خلل الذوق)، جفاف الفم، صعوبة البلع (عسر البلع)، التهاب بطانة الفم (التهاب الفم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الجلد، بما في ذلك الطفح الجلدي</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض شائعة ( قد تظهر لدى حتى 1 من كل 10</strong><strong>&nbsp;</strong><strong>أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف، والذي يمكن أن يكون شديدًا (النزف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئة (الالتهاب الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم الدم (تعفن الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد أنواع خلايا الدم البيضاء (العدلات)، مع الحمى</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ بالأعراض الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ&nbsp; طبيبك أو ممرضتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم تخزين تالفي في المستشفى أو العيادة بواسطة طبيبك. لذلك فإن المعلومات الآتية مخصصة بشكل أساسي لأخصائيي الرعاية الصحية.</p><p>&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق العبوة الكرتونية والقنينة بعد الحروف &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (2 درجة مئوية إلى 8 درجات مئوية). لا تجمده.</p><p>&nbsp;</p><p dir="RTL">يحفظ في العبوة الكرتونية الأصلية للحماية من الضوء.</p><p>&nbsp;</p><p dir="RTL">تحقق من المحلول بحثًا عن جسيمات أو تغير اللون قبل استخدام الدواء. يجب أن يكون المحلول عديم اللون إلى أصفر فاتح. لا تستخدم هذا الدواء إذا لم يكن شفافًا أو كان لونه متغيرًا أو يحتوي على جسيمات مرئية.</p><p>&nbsp;</p><p dir="RTL">يجب ألا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو نفايات المنزل. سيقوم أخصائي الرعاية الصحية بالتخلص من أي أدوية لم تعد تستخدم. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما مكونات دواء تالفي</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المادة الفعالة هي تالكيتاماب. يأتي تالفي بتركيزين مختلفين:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;مجم/مل - قنينة واحدة1.5&nbsp; مل تحتوي على 3&nbsp;مجم تالكيتاماب</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>40&nbsp;مجم/مل - قنينة واحدة 1 &nbsp;مل تحتوي على 40&nbsp;مجم تالكيتاماب</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي EDTA ملح ثنائي الھیدرات، حمض الأسيتيك الجليدي، بوليسوربات 20، ثلاثي هيدرات أسيتات الصوديوم، السكروز، ماء للحقن (انظر &quot;يحتوي تالفي على الصوديوم&quot; في القسم&nbsp;2).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو تالفي وما محتويات العبوة</strong></p><p dir="RTL">تالفي هو محلول للحقن (الحقن) وهو سائل عديم اللون إلى أصفر فاتح.</p><p dir="RTL">يتم توفير تالفي في عبوة كرتونية تحتوي على قنينة زجاجية&nbsp;واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">جانسن سيلاج انترناشونال ان فى</p><p dir="RTL">&nbsp;ترنهوتسويج 30</p><p dir="RTL">بي-2340 بيرس</p><p dir="RTL">بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p>باثيون مانيوفاكتشرينج سيرفيسز إل إل سي</p><p>5900 مارتن لوثر كينغ جونيور هايواي</p><p>جرينفيل، إن سي 27834</p><p>الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	للتواصل معنا، تفضل بزيارة الموقع الإلكتروني www.janssen.com/contact-us

	تمت آخر مراجعة لهذه النشرة في أغسطس 2023 .

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TALVEY 2 mg/mL solution for injection
TALVEY 40 mg/mL solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TALVEY 2 mg/mL solution for injection
One 1.5 mL vial contains 3 mg of talquetamab (2 mg/mL).

TALVEY 40 mg/mL solution for injection
One 1 mL vial contains 40 mg of talquetamab (40 mg/mL).

Talquetamab is a humanised immunoglobulin g4 proline, alanine, alanine (IgG4 PAA) bispecific antibody directed against G protein coupled receptor family C group 5 member D (GPRC5D) and the CD3 receptors, produced in Chinese hamster ovary cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

The solution is colourless to light yellow, with pH of 5.2 and osmolality of 287 290 mOsm/kg.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TALVEY is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti‑CD38 antibody and have demonstrated disease progression on the last therapy. This indication is approved under accelerated approval based on response rate [see CLINICAL STUDIES (14)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with TALVEY should be initiated and supervised by physicians experienced in the treatment of multiple myeloma.</p><p>&nbsp;</p><p>TALVEY should be administered by a healthcare professional with adequately‑trained medical personnel and appropriate medical equipment to manage severe reactions, including cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell‑associated neurotoxicity syndrome (ICANS).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Pre‑treatment medicinal products should be administered prior to each dose of TALVEY during the step‑up phase (see below).</p><p>TALVEY should be administered subcutaneously on a weekly or biweekly (every 2&nbsp;weeks) dosing schedule according to Table&nbsp;1. Patients who receive talquetamab according to the 0.4&nbsp;mg/kg weekly dosing schedule and have attained an adequate clinical response that is confirmed in at least two consecutive disease assessments can be considered for switch to the 0.8&nbsp;mg/kg biweekly dosing schedule.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended TALVEY dose</strong></p></td></tr><tr><td><p><strong>Dosing schedule</strong></p></td><td><p><strong>Phase</strong></p></td><td><p><strong>Day</strong></p></td><td><p><strong>TALVEY dose<sup>a</sup></strong></p></td></tr><tr><td rowspan="4"><p><strong>Weekly dosing schedule</strong></p></td><td rowspan="3"><p>Step‑up phase</p></td><td style="vertical-align:top"><p>Day&nbsp;1</p></td><td style="vertical-align:top"><p>0.01&nbsp;mg/kg</p></td></tr><tr><td><p>Day&nbsp;3<sup>b</sup></p></td><td><p>0.06&nbsp;mg/kg</p></td></tr><tr><td><p>Day&nbsp;5<sup>b</sup></p></td><td><p>0.4&nbsp;mg/kg</p></td></tr><tr><td><p>Treatment phase</p></td><td><p>Once a week thereafter<sup>c</sup></p></td><td><p>0.4&nbsp;mg/kg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5"><p><strong>Biweekly (every 2&nbsp;weeks) dosing schedule</strong></p></td><td rowspan="4"><p>Step‑up phase</p></td><td><p>Day&nbsp;1</p></td><td><p>0.01&nbsp;mg/kg</p></td></tr><tr><td><p>Day&nbsp;3<sup>b</sup></p></td><td><p>0.06&nbsp;mg/kg</p></td></tr><tr><td><p>Day&nbsp;5<sup>b</sup></p></td><td><p>0.4&nbsp;mg/kg</p></td></tr><tr><td><p>Day&nbsp;7<sup>b</sup></p></td><td><p>0.8&nbsp;mg/kg</p></td></tr><tr><td><p>Treatment phase</p></td><td><p>Once every 2&nbsp;weeks thereafter<sup>c</sup></p></td><td><p>0.8&nbsp;mg/kg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on actual body weight and administered subcutaneously.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose may be administered between 2&nbsp;to&nbsp;4&nbsp;days after the previous dose and may be given up to 7&nbsp;days after the previous dose to allow for resolution of adverse reactions.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maintain a minimum of 6 days between weekly doses and a minimum of 12 days between biweekly (every 2 weeks) doses.</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients should be instructed to remain within proximity of a healthcare facility and monitored for 48&nbsp;hours after administration of all doses within the TALVEY step‑up phase for signs and symptoms of CRS and ICANS (see section&nbsp;4.4).</p><p><em>&nbsp;</em></p><p><em>Duration of treatment</em></p><p>Patients should be treated with TALVEY until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p><u>Pre‑treatment</u></p><p>&nbsp;</p><p>The following pre‑treatment medicinal products must be administered 1&nbsp;to&nbsp;3&nbsp;hours before each dose of TALVEY during the step‑up phase to reduce the risk of CRS (see section&nbsp;4.4).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroid (oral or intravenous dexamethasone 16&nbsp;mg or equivalent)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamine (oral or intravenous diphenhydramine 50&nbsp;mg or equivalent)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antipyretics (oral or intravenous paracetamol 650&nbsp;mg&nbsp;to&nbsp;1&nbsp;000&nbsp;mg or equivalent)</p><p>&nbsp;</p><p>Pre‑treatment medicinal products should be administered prior to subsequent doses for patients who repeat doses within the TALVEY step‑up phase due to dose delays (see Table&nbsp;2) or for patients who experienced CRS (see Table&nbsp;3).</p><p>&nbsp;</p><p><em>Prevention of infection</em></p><p>Prior to starting treatment with TALVEY, prophylaxis should be considered for the prevention of infections, per local institutional guidelines.</p><p>&nbsp;</p><p><u>Dose delays</u></p><p><u>&nbsp;</u></p><p>If a dose of TALVEY is delayed, therapy should be restarted based on recommendations in Table&nbsp;2, and weekly or biweekly dosing should be resumed accordingly (see Posology above). Pre‑treatment medicinal products should be administered prior to restarting TALVEY, and patients should be monitored accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for restarting TALVEY after dose delay</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:bottom"><p><strong>Last dose</strong></p><p><strong>administered</strong></p></td><td style="vertical-align:bottom"><p><strong>Time from last dose administered</strong></p></td><td style="vertical-align:top"><p><strong>TALVEY recommendation*</strong></p></td></tr><tr><td rowspan="6"><p><strong>Weekly</strong></p><p><strong>dosing schedule</strong></p></td><td style="vertical-align:top"><p>0.01&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>More than 7&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td rowspan="2"><p>0.06&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>8 to 28&nbsp;days</p></td><td style="vertical-align:top"><p>Repeat 0.06&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>More than 28&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td rowspan="3"><p>0.4&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>8 to 35&nbsp;days</p></td><td style="vertical-align:top"><p>Repeat 0.4&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>36 to 56&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.06&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>More than 56&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="9"><p><strong>Biweekly</strong></p><p><strong>(every 2&nbsp;weeks) dosing schedule</strong></p></td><td style="vertical-align:top"><p>0.01&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>More than 7&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td rowspan="2"><p>0.06&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>8 to 28&nbsp;days</p></td><td style="vertical-align:top"><p>Repeat 0.06&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>More than 28&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td rowspan="3"><p>0.4&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>8 to 35&nbsp;days</p></td><td style="vertical-align:top"><p>Repeat 0.4&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>36 to 56&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.06&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>More than 56&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td rowspan="3"><p>0.8&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>14 to 35&nbsp;days</p></td><td style="vertical-align:top"><p>Repeat 0.8&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>36 to 56&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.4&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>More than 56&nbsp;days</p></td><td style="vertical-align:top"><p>Restart at 0.01&nbsp;mg/kg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp; Administer pretreatment medicinal products prior to restarting TALVEY. After restarting TALVEY, resume weekly or biweekly (every 2&nbsp;weeks) dosing accordingly (see section&nbsp;4.2).</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Dose modifications for adverse reactions</u></p><p>Dose delays may be required to manage toxicities related to TALVEY (see section&nbsp;4.4). See Table&nbsp;2 for recommendations on restarting TALVEY after a dose delay.</p><p><em>&nbsp;</em></p><p>See Tables&nbsp;3 and 4 for recommended actions for the management of CRS and ICANS. See Table&nbsp;6 for recommended dose modifications for other adverse reactions.</p><p><em>&nbsp;</em></p><p><em>Cytokine release syndrome (CRS)</em></p><p>CRS should be identified based on clinical presentation (see section&nbsp;4.4). Other causes of fever, hypoxia, and hypotension should be evaluated and treated. If CRS is suspected, TALVEY should be withheld until CRS resolves and should be managed according to the recommendations in Table&nbsp;3. Supportive therapy for CRS should be administered, which may include intensive care for severe or life‑threatening CRS. Laboratory testing should be considered to monitor for disseminated intravascular coagulation (DIC), haematology parameters, as well as pulmonary, cardiac, renal, and hepatic function.</p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for management of CRS</strong></p></td></tr><tr><td><p><strong>CRS Grade<sup>a</sup></strong></p></td><td><p><strong>TALVEY actions</strong></p></td><td><p><strong>Tocilizumab<sup>b</sup></strong></p></td><td><p><strong>Corticosteroids<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade&nbsp;1</strong></p><p>&nbsp;</p><p>Temperature &ge;&nbsp;38&deg;C<sup>d</sup></p></td><td style="vertical-align:top"><p>Withhold TALVEY until CRS resolves.</p><p>&nbsp;</p><p>Administer pre‑treatment medicinal product prior to next dose of TALVEY.</p></td><td style="vertical-align:top"><p>May be considered.</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade&nbsp;2</strong></p><p>&nbsp;</p><p>Temperature &ge;&nbsp;38&deg;C<sup>d</sup> with either:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension responsive to fluids and not requiring vasopressors, or</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of low‑flow nasal cannula<sup>e </sup>or blow‑by.</p></td><td style="vertical-align:top"><p>Withhold TALVEY until CRS resolves.</p><p>&nbsp;</p><p>Administer pre‑treatment medicinal products prior to next dose of TALVEY.</p><p>&nbsp;</p><p>Monitor patient for 48&nbsp;hours following the next dose of TALVEY. Instruct patients to remain within proximity of a healthcare facility during monitoring.</p></td><td style="vertical-align:top"><p>Administer tocilizumab<sup>c</sup> 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg).</p><p>&nbsp;</p><p>Repeat tocilizumab every 8&nbsp;hours as needed, if not responsive to intravenous fluids or increasing supplemental oxygen.</p><p>&nbsp;</p><p>Limit to a maximum of 3&nbsp;doses in a 24‑hour period; maximum total of 4&nbsp;doses.</p></td><td style="vertical-align:top"><p>If no improvement within 24&nbsp;hours of starting tocilizumab, administer methylprednisolone 1&nbsp;mg/kg intravenously twice daily, or dexamethasone 10&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>Continue corticosteroid use until the event is Grade&nbsp;1 or less, then taper over 3&nbsp;days.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade&nbsp;3</strong></p><p>&nbsp;</p><p>Temperature &ge;&nbsp;38&deg;C<sup>d</sup> with either:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring one vasopressor, with or without vasopressin, or</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of high‑flow nasal cannula<sup>e</sup>, facemask, non‑rebreather mask, or Venturi mask</p></td><td style="vertical-align:top"><p><u>Duration &lt;&nbsp;48&nbsp;hours</u></p><p><u>&nbsp;</u></p><p>Per Grade&nbsp;2.</p><p>&nbsp;</p><p><u>Recurrent or</u></p><p><u>Duration &ge;&nbsp;48&nbsp;hours</u></p><p><u>&nbsp;</u></p><p>Permanently discontinue TALVEY.</p></td><td style="vertical-align:top"><p>Administer tocilizumab 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg).</p><p>&nbsp;</p><p>Repeat tocilizumab every 8&nbsp;hours as needed, if not responsive to intravenous fluids or increasing supplemental oxygen.</p><p>&nbsp;</p><p>Limit to a maximum of 3&nbsp;doses in a 24‑hour period; maximum total of 4&nbsp;doses.</p></td><td style="vertical-align:top"><p>If no improvement, administer methylprednisolone 1&nbsp;mg/kg intravenously twice daily or dexamethasone (e.g.,&nbsp;10&nbsp;mg intravenously every 6&nbsp;hours).</p><p>&nbsp;</p><p>Continue corticosteroid use until the event is Grade&nbsp;1 or less, then taper over 3&nbsp;days.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade&nbsp;4</strong></p><p>&nbsp;</p><p>Temperature &ge;&nbsp;38&deg;C<sup>d</sup> with either:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring multiple vasopressors (excluding vasopressin), or</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oxygen requirement of positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation, and mechanical ventilation)</p></td><td style="vertical-align:top"><p>Permanently discontinue TALVEY.</p></td><td style="vertical-align:top"><p>Administer tocilizumab 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg).</p><p>&nbsp;</p><p>Repeat tocilizumab every 8&nbsp;hours as needed, if not responsive to intravenous fluids or increasing supplemental oxygen.</p><p>&nbsp;</p><p>Limit to a maximum of 3&nbsp;doses in a 24‑hour period; maximum total of 4&nbsp;doses.</p></td><td style="vertical-align:top"><p>As above or administer methylprednisolone 1&nbsp;000&nbsp;mg intravenously per day for 3&nbsp;days, per physician discretion.</p><p>&nbsp;</p><p>If no improvement or if condition worsens, consider alternate immunosuppressants.<sup>c</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on ASTCT grading for CRS (Lee et al 2019).</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to tocilizumab prescribing information for details.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treat unresponsive CRS per institutional guidelines.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anticytokine therapy (e.g., tocilizumab or corticosteroids).</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low‑flow nasal cannula is &le;&nbsp;6&nbsp;L/min, and high‑flow nasal cannula is &gt;&nbsp;6&nbsp;L/min.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Neurologic toxicity, including ICANS</em></p><p>At the first sign of neurologic toxicity, including ICANS, TALVEY should be withheld and neurology evaluation should be considered. Other causes of neurologic symptoms should be ruled out. Supportive therapy should be provided, which may include intensive care, for severe or life‑threatening ICANS (see section&nbsp;4.4). Management recommendations for ICANS are summarised in Table&nbsp;4.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for management of ICANS</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>ICANS Grade<sup>a, b</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>Concurrent CRS</strong></p></td><td style="vertical-align:bottom"><p><strong>No concurrent CRS</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade&nbsp;1</strong></p><p>&nbsp;</p><p>ICE<sup>c</sup> score&nbsp;7‑9</p><p>&nbsp;</p><p>or depressed level of consciousness<sup>d</sup>: awakens spontaneously.</p></td><td style="vertical-align:top"><p>Management of CRS per Table&nbsp;3.</p><p>&nbsp;</p><p>Monitor neurologic symptoms and consider neurology consultation and evaluation, per physician discretion.</p></td><td style="vertical-align:top"><p>Monitor neurologic symptoms and consider neurology consultation and evaluation, per physician discretion.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Withhold TALVEY until ICANS resolves.</p><p>&nbsp;</p><p>Consider non‑sedating, anti‑seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade&nbsp;2</strong></p><p>&nbsp;</p><p>ICE<sup>c</sup> score&nbsp;3‑6</p><p>&nbsp;</p><p>or depressed level of consciousness<sup>d</sup>: awakens to voice.</p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table&nbsp;3 for management of CRS.</p><p>&nbsp;</p><p>If no improvement after starting tocilizumab, administer dexamethasone<sup>e</sup> 10&nbsp;mg intravenously every 6&nbsp;hours if not already taking other corticosteroids. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>e</sup> 10&nbsp;mg intravenously every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Withhold TALVEY until ICANS resolves.</p><p>&nbsp;</p><p>Consider non‑sedating, anti‑seizure medicines (e.g., levetiracetam) for seizure prophylaxis. Consider neurology consultation and other specialists for further evaluation, as needed.</p><p>&nbsp;</p><p>Monitor patient for 48&nbsp;hours following the next dose of TALVEY. Instruct patients to remain within proximity of a healthcare facility during&nbsp; monitoring.</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade&nbsp;3</strong></p><p>&nbsp;</p><p>ICE<sup>c</sup> score&nbsp;0‑2</p><p>(If ICE score is 0, but the patient is arousable (e.g., awake with global aphasia) and able to perform assessment)</p><p>&nbsp;</p><p>or depressed level of consciousness<sup>d</sup>: awakens only to tactile stimulus,</p><p>&nbsp;</p><p>or seizures<sup>d</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any clinical seizure, focal or generalised, that resolves rapidly, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non‑convulsive seizures on electroencephalogram (EEG) that resolve with intervention,</p><p>&nbsp;</p><p>or raised intracranial pressure: focal/local oedema on neuroimaging<sup>d</sup>.</p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table&nbsp;3 for management of CRS.</p><p>&nbsp;</p><p>Administer dexamethasone<sup>e</sup> 10&nbsp;mg intravenously with the first dose of tocilizumab and repeat dose every 6&nbsp;hours. Continue dexamethasone use until resolution to&nbsp;Grade&nbsp;1 or less, then taper.</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>e</sup> 10&nbsp;mg intravenously every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider non‑sedating, anti‑seizure medicines (e.g., levetiracetam) for seizure prophylaxis. Consider neurology consultation and other specialists for further evaluation, as needed.</p><p><u>&nbsp;</u></p><p><u>First Occurrence:</u></p><p>Withhold TALVEY until ICANS resolves.</p><p>&nbsp;</p><p>Monitor patient for 48&nbsp;hours following the next dose of TALVEY. Instruct patients to remain within proximity of a healthcare facility during monitoring.</p><p>&nbsp;</p><p><u>Recurrent:</u></p><p>Permanently discontinue TALVEY.</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade&nbsp;4</strong></p><p>&nbsp;</p><p>ICE<sup>c</sup> score&nbsp;0</p><p>(Patient is unarousable and unable to perform ICE assessment)</p><p>&nbsp;</p><p>or depressed level of consciousness<sup>d</sup> either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stupor or coma,</p><p>&nbsp;</p><p>or seizures<sup>d</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life‑threatening prolonged seizure (&gt;&nbsp;5&nbsp;minutes), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repetitive clinical or electrical seizures without return to baseline in between,</p><p>&nbsp;</p><p>or motor findings<sup>d</sup>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deep focal motor weakness such as hemiparesis or paraparesis,</p><p>&nbsp;</p><p>or raised intracranial pressure/cerebral oedema<sup>d</sup>, with signs/symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diffuse cerebral oedema on neuroimaging, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decerebrate or decorticate posturing, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cranial nerve VI palsy, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; papilledema, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&rsquo;s triad.</p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table&nbsp;3 for management of CRS.</p><p>&nbsp;</p><p>Administer dexamethasone<sup>e</sup> 10&nbsp;mg intravenously and repeat dose every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p><p>&nbsp;</p><p>Alternatively, consider administration of methylprednisolone 1&nbsp;000&nbsp;mg per day intravenously with first dose of tocilizumab, and continue methylprednisolone 1&nbsp;000&nbsp;mg per day intravenously for 2&nbsp;or&nbsp;more&nbsp;days.</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>e </sup>10&nbsp;mg intravenously and repeat dose every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p><p>&nbsp;</p><p>Alternatively, consider administration of methylprednisolone 1 000&nbsp;mg per day intravenously for 3&nbsp;days; if improves, then manage as above.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Permanently discontinue TALVEY.</p><p>&nbsp;</p><p>Consider non‑sedating, anti‑seizure medicines (e.g., levetiracetam) for seizure prophylaxis. Consider neurology consultation and other specialists for further evaluation, as needed.</p><p>&nbsp;</p><p>In case of raised intracranial pressure/cerebral oedema, refer to local institutional guidelines for management.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Management is determined by the most severe event, not attributable to any other cause.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASTCT 2019 grading for ICANS.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If patient is arousable and able to perform Immune Effector Cell‑Associated Encephalopathy (ICE) Assessment, assess: <strong>Orientation</strong> (oriented to year, month, city, hospital = 4&nbsp;points); <strong>Naming</strong> (name 3 objects, e.g., point to clock, pen, button = 3&nbsp;points); <strong>Following Commands</strong> (e.g., &ldquo;show me 2&nbsp;fingers&rdquo; or &ldquo;close your eyes and stick out your tongue&rdquo; = 1&nbsp;point); <strong>Writing</strong> (ability to write a standard sentence = 1&nbsp;point; and <strong>Attention</strong> (count backwards from 100 by ten = 1&nbsp;point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0&nbsp;points.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attributable to no other cause.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All references to dexamethasone administration are dexamethasone or equivalent</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for management of neurologic toxicity (excluding ICANS)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Severity</strong><strong><sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Actions</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Neurologic Toxicity<sup>a</sup> (excluding ICANS)</p></td><td style="vertical-align:top"><p>Grade&nbsp;1</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until neurologic toxicity symptoms resolve or stabilise.<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2</p><p>Grade&nbsp;3 (First occurrence)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until neurologic toxicity symptoms improve to Grade&nbsp;1 or less.<sup>b</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy.</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 (Recurrent)</p><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue TALVEY.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version&nbsp;4.03.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;2 for recommendations on restarting TALVEY after dose delays.</p></td><td><p>&nbsp;</p></td></tr></thead></table><p><em>&nbsp;</em></p><p><em>Other adverse reactions</em></p><p>The recommended dose modifications for other adverse reactions are provided in Table&nbsp;6.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose modifications for other adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Severity</strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Serious infections</p><p>(see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>All Grades</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not administer TALVEY step‑up dosing schedule in patients with active infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY in the step‑up phase until infection resolves.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3‑4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY during the treatment phase until infection improves to Grade&nbsp;2 or better.</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Cytopenias</p><p>(see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>Absolute neutrophil count less than 0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until absolute neutrophil count is 0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L or higher.</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until absolute neutrophil count is 1.0&nbsp;&times;&nbsp;10<sup>9</sup>/L or higher and fever resolves.</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin less than 8&nbsp;g/dL</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until haemoglobin is 8&nbsp;g/dL or higher.</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count less than 25&nbsp;000/&micro;L</p><p>&nbsp;</p><p>Platelet count between 25&nbsp;000/&micro;L and 50&nbsp;000/&micro;L with bleeding</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until platelet count is 25&nbsp;000/&micro;L or higher and no evidence of bleeding.</p></td></tr><tr><td style="vertical-align:top"><p>Oral toxicity, including weight loss</p><p>(see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>Toxicity not responding to supportive care</p></td><td style="vertical-align:top"><p>Interrupt TALVEY until stabilisation or improvement, and consider restarting on modified schedule as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If current dose is 0.4&nbsp;mg/kg every week, change to 0.4&nbsp;mg/kg every two&nbsp;weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If current dose is 0.8&nbsp;mg/kg every two&nbsp;weeks, change to 0.8&nbsp;mg/kg every four&nbsp;weeks</p></td></tr><tr><td style="vertical-align:top"><p>Skin reactions, including nail disorders</p><p>(see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>Grade&nbsp;3‑4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until adverse reaction improves to Grade&nbsp;1 or baseline.</p></td></tr><tr><td style="vertical-align:top"><p>Other non‑haematologic adverse reactions<sup>a</sup></p><p>(see section&nbsp;4.8)</p></td><td style="vertical-align:top"><p>Grade&nbsp;3‑4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TALVEY until adverse reaction improves to Grade&nbsp;1 or baseline.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI‑CTCAE), Version 4.03.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of TALVEY in the paediatric population in the treatment of multiple myeloma.</p><p>&nbsp;</p><p><em>Elderly (65&nbsp;years of age and older)</em></p><p>No dose adjustment is required (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dose adjustment is recommended for patients with mild or moderate renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is recommended for patients with mild hepatic impairment (see section&nbsp;5.2). Limited or no data are available in patients with moderate and severe hepatic impairment.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>TALVEY is for subcutaneous use.</p><p>&nbsp;</p><p>The required volume of TALVEY should be injected into the subcutaneous tissue of the abdomen (preferred injection site). Alternatively, TALVEY may be injected into the subcutaneous tissue at other sites (e.g., thigh). If multiple injections are required, TALVEY injections should be at least 2&nbsp;cm apart.</p><p>&nbsp;</p><p>TALVEY must not be injected into tattoos or scars or areas where the skin is red, bruised, tender, hard or not intact.</p><p>&nbsp;</p><p>For instructions on handling of the medicinal product before administration, see section&nbsp;6.6.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Cytokine release syndrome (CRS)</u></p><p>&nbsp;</p><p>CRS, including life‑threatening or fatal reactions, may occur in patients receiving TALVEY (see section&nbsp;4.8). Clinical signs and symptoms of CRS may include but are not limited to pyrexia, hypotension, chills, hypoxia, headache, tachycardia and elevated transaminases. Potentially life‑threatening complications of CRS may include cardiac dysfunction, acute respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation (DIC).</p><p>&nbsp;</p><p>TALVEY therapy should be initiated with step‑up phase dosing and pre‑treatment medicinal products (corticosteroids, antihistamine, and antipyretics) should be administered prior to each dose of TALVEY during the step‑up phase to reduce the risk of CRS. Patients should be monitored following administration accordingly. In patients who experience CRS following their previous dose, pre‑treatment medicinal products should be administered prior to the next TALVEY dose (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Subjects who experienced Grade&nbsp;3 or higher CRS with any previous T cell redirection therapy were excluded from clinical studies. It cannot be excluded that prior severe CRS with chimeric antigen receptor (CAR) T‑cell therapy or other T‑cell engagers might impact on the safety of TALVEY. The potential benefits of treatment should be carefully weighed against the risk of neurologic events, and heightened caution should be exercised when administering TALVEY to these patients.</p><p>&nbsp;</p><p>Patients should be counselled to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, patients should be immediately evaluated for hospitalisation and treatment with supportive care, tocilizumab and/or corticosteroids, should be instituted based on severity. The use of myeloid growth factors, particularly granulocyte macrophage‑colony stimulating factor (GM‑CSF), should be avoided during CRS. TALVEY should be withheld until CRS resolves (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Neurologic toxicity, including ICANS</u></p><p>&nbsp;</p><p>Serious or life‑threatening neurologic toxicities, including ICANS have occurred following treatment with TALVEY (see section&nbsp;4.8).</p><p>&nbsp;</p><p>ICANS, including fatal reactions, have occurred following treatment with TALVEY. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Clinical signs and symptoms of ICANS may include but are not limited to confusional state, depressed level of consciousness, disorientation, somnolence, lethargy, and bradyphrenia.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of neurologic toxicities and treated promptly. Patients should be counselled to seek medical attention should signs or symptoms of neurologic toxicities including ICANS occur. At the first sign of neurologic toxicities including ICANS, the patient should be immediately evaluated and supportive care should be provided based on severity. Patients who experience Grade&nbsp;2 or higher ICANS should be instructed to remain within proximity of a healthcare facility and monitored for signs and symptoms for 48&nbsp;hours following the next dose of TALVEY.</p><p>&nbsp;</p><p>For ICANS and other neurologic toxicities, TALVEY should be withheld or discontinued based on severity and management recommendations should be followed as indicated in Table&nbsp;4 (see section&nbsp;4.2).</p><p>&nbsp;</p><p>There are no data on use of talquetamab in patients with CNS involvement of myeloma or other clinically relevant CNS pathologies as a result of their exclusion from the study due to the potential risk of ICANS.</p><p>&nbsp;</p><p>Due to the potential for ICANS, patients should be instructed to avoid driving or operating machines during the step‑up phase and for 48&nbsp;hours after completion of the step‑up phase, and in the event of new onset of any neurological symptoms, until symptoms resolve (see section&nbsp;4.7).</p><p>&nbsp;</p><p><em>Management of neurologic toxicities</em></p><p>At the first sign of neurologic toxicity, including ICANS, neurology evaluation should be considered. Other causes of neurologic symptoms should be ruled out. TALVEY should be withheld until adverse reaction resolves (see Table&nbsp;4). Intensive care and supportive therapy should be provided for severe or life‑threatening neurologic toxicities.</p><p>&nbsp;</p><p><u>Oral toxicity</u></p><p><u>&nbsp;</u></p><p>Oral toxicities, including dysgeusia, dry mouth, dysphagia, and stomatitis occur very commonly following treatment with TALVEY (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of oral toxicity. Patients should be counselled to seek medical attention should signs or symptoms of oral toxicity occur, and supportive care should be provided. Supportive care may include saliva stimulating agents, steroid mouth wash, or consultation with a nutritionist. TALVEY should be interrupted or less frequent dosing should be considered (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Over time, notable weight loss may occur (see section&nbsp;4.8). Weight change should be monitored regularly during therapy. Clinically significant weight loss should be further evaluated. TALVEY should be interrupted or less frequent dosing should be considered (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Serious infections</u></p><p><u>&nbsp;</u></p><p>Serious infections, including life‑threatening or fatal infections, have been reported in patients receiving TALVEY (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of infection prior to and during treatment with TALVEY and treated appropriately. Prophylactic antimicrobials should be administered according to local guidelines. TALVEY should not be administered in patients with active serious infection. TALVEY should be withheld as indicated (see section&nbsp;4.2). Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur.</p><p>&nbsp;</p><p><u>Hypogammaglobulinaemia</u></p><p>&nbsp;</p><p>Hypogammaglobulinaemia has been reported in patients receiving TALVEY (see section&nbsp;4.8).</p><p>Immunoglobulin levels should be monitored during treatment with TALVEY. Intravenous or subcutaneous immunoglobulin therapy was used to treat hypogammaglobulinaemia patients. Patients should be treated according to local institutional guidelines, including infection precautions, antibiotic or antiviral prophylaxis, and administration of immunoglobulin replacement.</p><p>&nbsp;</p><p><u>Cytopenias</u></p><p>&nbsp;</p><p>Treatment‑emergent Grade&nbsp;3 or 4 neutropenia, febrile neutropenia and thrombocytopenia have been observed in patients who received TALVEY. A majority of cytopenias occurred during the first 8 to 10&nbsp;weeks. Complete blood counts should be monitored at baseline and periodically during treatment. Supportive care should be provided per local institutional guidelines.</p><p>Patients with neutropenia should be monitored for signs of infection. TALVEY should be withheld as warranted (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Skin reactions</u></p><p>&nbsp;</p><p>TALVEY can cause skin reactions including rash, maculo‑papular rash, erythema, erythematous rash, as well as nail disorders (see section&nbsp;4.8). Skin reactions including rash progression should be monitored for early intervention and treatment with corticosteroids. For Grade&nbsp;3 or higher, or worsening Grade&nbsp;1 or 2 rashes, oral steroids should also be administered. For non‑rash skin reactions dose modification may be considered (see Table&nbsp;6).</p><p>For skin reactions and nail disorders, TALVEY should be withheld based on severity and institutional guidelines should be followed (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><u>Vaccines</u></p><p>&nbsp;</p><p>Immune response to vaccines may be reduced when taking TALVEY. The safety of immunisation with live viral vaccines during or following TALVEY treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 4&nbsp;weeks prior to the start of treatment, during treatment, and at least 4&nbsp;weeks after treatment.</p><p>For unexpected exposure during pregnancy, see section&nbsp;4.6.</p><p>&nbsp;</p><p><u>Women of child‑bearing potential/contraception</u></p><p>&nbsp;</p><p>Pregnancy status of females of child‑bearing potential should be verified prior to initiating treatment with TALVEY. Females of reproductive potential should use effective contraception during treatment and for 3&nbsp;months after the last dose of TALVEY (see section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p><em>&nbsp;</em></p><p>Talquetamab causes release of cytokines (see section&nbsp;5.1) that may suppress activity of cytochrome P450 (CYP) enzymes, potentially resulting in increased exposure of CYP substrates. The highest risk of drug‑drug interaction is expected to occur from initiation of talquetamab step‑up phase up to 9&nbsp;days after the first treatment dose and during and after CRS (see section&nbsp;4.4). Monitor for toxicity or concentrations of medicinal products that are CYP (e.g., CYP2C9, CYP2C19, CYP3A4/5, CYP2D6) substrates where minimal concentration changes may lead to serious adverse reactions. The dose of concomitant CYP (e.g., CYP2C9, CYP2C19, CYP3A4/5, CYP2D6) substrate drugs should be adjusted as needed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in females</u></p><p>&nbsp;</p><p>Pregnancy status of females of child‑bearing potential should be verified prior to initiating treatment with TALVEY.</p><p>&nbsp;</p><p>Females of reproductive potential should use effective contraception during treatment and for 3&nbsp;months after the last dose of TALVEY.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no available data on the use of TALVEY in pregnant women or animal data to assess the risk of TALVEY in pregnancy. Human IgG is known to cross the placenta after the first trimester of pregnancy. Therefore, talquetamab has the potential to be transmitted from the mother to the developing foetus. The effects of TALVEY on the developing foetus are unknown. TALVEY is not recommended for women who are pregnant or for women of childbearing potential not using contraception.</p><p>&nbsp;</p><p>If TALVEY is taken during pregnancy, a reduced immune response to vaccines may be expected in newborns. Consequently, newborn vaccinations with live vaccines such as BCG vaccine should be postponed until 4&nbsp;weeks.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether talquetamab is excreted in human milk. Because the potential for serious adverse reactions in breast‑fed infants is unknown for TALVEY, patients should not breast‑feed during treatment with TALVEY and for at least 3&nbsp;months after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the effect of talquetamab on fertility. Effects of talquetamab on male and female fertility have not been evaluated in animal studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TALVEY has major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Due to the potential for ICANS, patients receiving TALVEY are at risk of depressed level of consciousness (see section&nbsp;4.4). Patients should be instructed to avoid driving or operating machines during the step‑up phase and for 48&nbsp;hours after completion of the step‑up phase (see section&nbsp;4.2), and in the event of new onset of any neurological symptoms, until symptoms resolve.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequent adverse reactions were CRS (77%), dysgeusia (72%), hypogammaglobulinaemia (67%), nail disorder (56%), musculoskeletal pain (48%), anaemia (47%), skin disorder (43%), fatigue (43%), weight decreased (40%), rash (39%), dry mouth (36%), neutropenia (35%), pyrexia (33%), xerosis (32%), thrombocytopenia (30%), upper respiratory tract infection (29%), lymphopenia (27%), dysphagia (24%), diarrhoea (25%), pruritus (23%), cough (23%), pain (22%), decreased appetite (22%) and headache (20%).</p><p>&nbsp;</p><p>Serious adverse reactions reported in patients included CRS (13%), pyrexia (5%), ICANS (3.8%), sepsis (3.8%), COVID‑19 (3.2%), bacterial infection (2.4%), pneumonia (2.4%), viral infection (2.4%), neutropenia (2.1%) and pain (2.1%).</p><p>&nbsp;</p><p>The most frequent adverse reactions leading to treatment discontinuation were ICANS (1.1%) and weight decreased (0.9%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The safety of TALVEY was evaluated in 339 adult patients with relapsed or refractory multiple myeloma, including patients treated with TALVEY at the recommended dosing regimen with or without prior T cell redirection therapy in MonumenTAL‑1. The median duration of treatment was 7.4 (range: 0.0 to 32.9) months.</p><p>&nbsp;</p><p>Table&nbsp;7 summarises adverse reactions reported in patients who received TALVEY. The safety data of TALVEY was also evaluated in the All Treated population (N=501) with no additional adverse reactions identified.</p><p>&nbsp;</p><p>Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); very rare (&lt;&nbsp;1/10&nbsp;000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Table&nbsp;7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in patients with multiple myeloma treated with TALVEY in MonumenTAL‑1 (N=339) </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>System Organ Class</strong></p><p>Adverse Reaction</p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>category</strong></p></td><td style="vertical-align:top"><p><strong>Any Grade</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3 or 4 (%)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial infection<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>40 (12%)</p></td><td style="vertical-align:bottom"><p>11 (3.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infection<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>39 (12%)</p></td><td style="vertical-align:bottom"><p>1 (0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>COVID‑19<sup>*#</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>63 (19%)</p></td><td style="vertical-align:bottom"><p>10 (2.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>98 (29%)</p></td><td style="vertical-align:bottom"><p>7 (2.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis<sup>*#</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:bottom"><p>15 (4.4%)</p></td><td style="vertical-align:bottom"><p>14 (4.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia<sup>*</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:bottom"><p>23 (7%)</p></td><td style="vertical-align:bottom"><p>11 (3.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Viral infection<sup>*</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:bottom"><p>23 (7%)</p></td><td style="vertical-align:bottom"><p>6 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>119 (35%)</p></td><td style="vertical-align:bottom"><p>103 (30%)</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>158 (47%)</p></td><td style="vertical-align:bottom"><p>99 (29%)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>101 (30%)</p></td><td style="vertical-align:bottom"><p>71 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>91 (27%)</p></td><td style="vertical-align:bottom"><p>83 (25%)</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:bottom"><p>62 (18%)</p></td><td style="vertical-align:bottom"><p>38 (11%)</p></td></tr><tr><td style="vertical-align:top"><p>Haemorrhage<sup>1</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:bottom"><p>27 (8%)</p></td><td style="vertical-align:bottom"><p>5 (1.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:bottom"><p>7 (2.1%)</p></td><td style="vertical-align:bottom"><p>7 (2.1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cytokine release syndrome</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>260 (77%)</p></td><td style="vertical-align:top"><p>5 (1.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinaemia<sup>2</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>227 (67%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>76 (22%)</p></td><td style="vertical-align:bottom"><p>4 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>55 (16%)</p></td><td style="vertical-align:bottom"><p>12 (3.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphataemia<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>49 (15%)</p></td><td style="vertical-align:bottom"><p>21 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>35 (11%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune effector cell‑associated neurotoxicity syndrome<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>26 (10%)</p></td><td style="vertical-align:bottom"><p>6 (2.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Encephalopathy<sup>3</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>36 (11%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>69 (20%)</p></td><td style="vertical-align:bottom"><p>2 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Motor dysfunction<sup>4</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>38 (11%)</p></td><td style="vertical-align:bottom"><p>2 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>42 (12%)</p></td><td style="vertical-align:bottom"><p>8 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Sensory neuropathy<sup>5</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>34 (10%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>78 (23%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>6#</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>39 (12%)</p></td><td style="vertical-align:bottom"><p>5 (1.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Oral Pain<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>42 (12%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia<sup>&Dagger;7</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>245 (72%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth<sup>&Dagger;</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>122 (36%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dysphagia</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>82 (24%)</p></td><td style="vertical-align:bottom"><p>3 (0.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>84 (25%)</p></td><td style="vertical-align:bottom"><p>4 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis<sup>8</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>67 (20%)</p></td><td style="vertical-align:bottom"><p>4 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>64 (19%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>61 (18%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>35 (10%)</p></td><td style="vertical-align:bottom"><p>1 (0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>34 (10%)</p></td><td style="vertical-align:bottom"><p>2 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>132 (39%)</p></td><td style="vertical-align:bottom"><p>12 (3.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Skin disorder<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>145 (43%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Xerosis<sup>9</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>109 (32%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>79 (23%)</p></td><td style="vertical-align:bottom"><p>1 (0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Nail disorder<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>191 (56%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>30 (9%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>164 (48%)</p></td><td style="vertical-align:bottom"><p>12 (3.5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrate site conditions</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>147 (43%)</p></td><td style="vertical-align:bottom"><p>12 (3.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>134 (40%)</p></td><td style="vertical-align:bottom"><p>11 (3.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>113 (33%)</p></td><td style="vertical-align:bottom"><p>6 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Pain<sup>*</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>76 (22%)</p></td><td style="vertical-align:bottom"><p>7 (2.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Oedema<sup>10</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>59 (17%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction<sup>11</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>45 (13%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>39 (12%)</p></td><td style="vertical-align:bottom"><p>1 (0.3%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fibrinogen decreased</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>52 (15%)</p></td><td style="vertical-align:bottom"><p>12 (3.5%)</p></td></tr><tr><td style="vertical-align:top"><p>aPTT prolonged</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>49 (15%)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Transaminase elevation<sup>12</sup></p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>48 (14%)</p></td><td style="vertical-align:bottom"><p>12 (3.5%)</p></td></tr><tr><td style="vertical-align:top"><p>INR increased</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>47 (14%)</p></td><td style="vertical-align:bottom"><p>1 (0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Gamma‑glutamyltransferase increased</p></td><td style="vertical-align:bottom"><p>Very common</p></td><td style="vertical-align:bottom"><p>36 (11%)</p></td><td style="vertical-align:bottom"><p>16 (4.7%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Adverse reactions are coded using MedDRA Version 24.0.</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per CTCAE v4.03, maximum toxicity grade for dysgeusia is 2 and maximum toxicity grade for dry mouth is 3.</p><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grouped term</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contains fatal outcome(s)</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemorrhage includes: Conjunctival haemorrhage, Epistaxis, Haematoma, Haematuria, Lower gastrointestinal haemorrhage, Periorbital haemorrhage, Petechiae, Rectal haemorrhage, Subdural haematoma and Vaginal haemorrhage.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia includes: hypogammaglobulinaemia and/or subjects with laboratory IgG levels below 500&nbsp;mg/dL following treatment with talquetamab.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes: agitation, amnesia, aphasia, bradyphrenia, confusional state, delirium, disorientation, encephalopathy, hallucination, lethargy, memory impairment, restlessness, sleep disorder and somnolence.</p><p><sup>4</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Motor dysfunction includes: dysgraphia, dysphonia, gait disturbance, muscle spasms, muscular weakness and tremor.</p><p><sup>5</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Sensory neuropathy includes: dysaesthesia, hypoaesthesia, hypoaesthesia oral, neuralgia, peripheral sensory neuropathy, sciatica and vestibular neuronitis.</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea includes: acute respiratory failure, dyspnoea, dyspnoea exertional, respiratory failure and tachypnoea.</p><p><sup>7</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysgeusia includes: ageusia, dysgeusia, hypogeusia and taste disorder.</p><p><sup>8</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomatitis includes: cheilitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral mucosal erythema, oral pain, stomatitis, swollen tongue, tongue discomfort, tongue erythema, tongue oedema and tongue ulceration.</p><p><sup>9</sup>&nbsp;&nbsp;&nbsp;&nbsp; Xerosis includes: dry eye, dry skin and xerosis.</p><p><sup>10</sup>&nbsp;&nbsp;&nbsp; Oedema includes: fluid retention, gingival swelling, hypervolaemia, joint swelling, lip swelling, oedema, oedema peripheral, periorbital oedema, peripheral swelling and swelling.</p><p><sup>11</sup>&nbsp;&nbsp;&nbsp; Injection site reaction includes: injection site discomfort, injection site erythema, injection site haemorrhage, injection site inflammation, injection site irritation, injection site plaque, injection site pruritus, injection site rash and injection site reaction.</p><p><sup>12</sup>&nbsp;&nbsp;&nbsp; Transaminase elevation includes: alanine aminotransferase increased, aspartate aminotransferase increased, and transaminases increased.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Cytokine release syndrome</em></p><p>In MonumenTAL‑1 (N=339), CRS occurred in 77% of patients. Most events were Grade&nbsp;1 or 2, with Grade&nbsp;3 events occurring in 1.5% of patients. Thirty one percent (31%) of patients experienced more than one CRS event. Most events occurred during the step‑up phase following the 0.01&nbsp;mg/kg dose (29%), the 0.06&nbsp;mg/kg dose (44%), the 0.3&nbsp;mg/kg dose (for patients who received biweekly [every 2&nbsp;weeks] dosing; 33%), or the initial treatment dose (0.4&nbsp;mg/kg [30%] or 0.8&nbsp;mg/kg [12%]). Less than 4% of CRS events occurred from week&nbsp;5 onward; all events were Grade&nbsp;1. The median time to onset of CRS was 27&nbsp;hours from the last dose, 91% of events occurred within 48&nbsp;hours from the last dose, and the median duration was 17&nbsp;hours. Tocilizumab, corticosteroids and tocilizumab in combination with corticosteroids were used to treat CRS in 39%, 5% and 3.5% of CRS events, respectively. Clinical signs and symptoms of CRS may include but are not limited to pyrexia (76%), hypotension (15%), chills (12%), hypoxia (7%), headache (4.7%), tachycardia (5%) and elevated transaminases (aspartate aminotransferase [1.5%] and alanine aminotransferase [0.9%]).</p><p>&nbsp;</p><p><em>Neurologic toxicities</em></p><p><em>&nbsp;</em></p><p>In MonumenTAL‑1 (N=339), neurologic toxicity events were reported in 29% of patients receiving TALVEY. Neurologic toxicity events were Grade&nbsp;1 (17%), Grade&nbsp;2 (11%), Grade&nbsp;3 (2.3%) or Grade&nbsp;4 (0.3%). The most frequently reported neurologic toxicity event was headache (9%).</p><p><em>&nbsp;</em></p><p>ICANS were only collected for Phase&nbsp;2 in MonumenTAL‑1. Of the 265&nbsp;patients in Phase 2, ICANS occurred in 9.8% (n=26) of patients. Most events were Grade&nbsp;1 or 2, with Grade&nbsp;3 and 4 events occurring in 2.3% of patients. The most frequent clinical manifestation of ICANS reported were confusional state (3.8%), disorientation (1.9%), somnolence (1.9%) and depressed level of consciousness (1.9%). Sixty‑eight percent (68%) were concurrent with CRS (during or within 7&nbsp;days of CRS resolution). Three percent (3%) of patients experienced more than one ICANS event. In addition, one fatal ICANS event was reported in MonumenTAL‑1. Most patients experienced ICANS during the step‑up phase following the 0.01&nbsp;mg/kg dose, the 0.06&nbsp;mg/kg dose, or the initial treatment dose (0.4&nbsp;mg/kg and 0.8&nbsp;mg/kg) (3% each). The median time to onset of ICANS was 28&nbsp;hours from the last dose, 68% of events started within 48&nbsp;hours from the last dose, 32% of events occurred after 48 hours, and the median duration of ICANS was 9&nbsp;hours.</p><p><u>&nbsp;</u></p><p><em>Oral toxicity</em></p><p>In MonumenTAL‑1 (N=339), seventy‑eight percent (78%) of patients had Grade&nbsp;1 or 2 events, with Grade&nbsp;3 events occurring in 2% of patients. Oral toxicity events included dysgeusia, dry mouth, dysphagia, and stomatitis were reported.</p><p>&nbsp;</p><p><em>Serious infections</em></p><p>In MonumenTAL‑1 (N=339), Grade&nbsp;3 or Grade&nbsp;4 infections occurred in 19% of patients; fatal infections occurred in 1.5% of patients ‑ COVID‑19 pneumonia, fungal sepsis, infection and septic shock. The most frequently reported (&ge;&nbsp;2%) Grade&nbsp;3 or 4 infection was pneumonia. Febrile neutropenia was observed in 1% of patients with 1.2% experiencing serious febrile neutropenia. See section&nbsp;4.4 for monitoring and management guidance.</p><p>&nbsp;</p><p><em>Hypogammaglobulinaemia</em></p><p>Post baseline IgG values of less than 500&nbsp;mg/dl consistent with hypogammaglobulinaemia have been reported in 64% of patients treated with talquetamab at the 0.4&nbsp;mg/kg weekly dose schedule, 66% of patients at the 0.8&nbsp;mg/kg biweekly dose schedule and in 71% of patients with prior T cell redirection therapy (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Skin reactions</em></p><p>In MonumenTAL‑1 (N=339), the majority of rash cases were Grade&nbsp;1 or 2, with Grade&nbsp;3 events occurring in 3.5% of patients. The median time to onset from the first treatment dose for rash was 22&nbsp;days. The majority of non‑rash skin toxicities were Grade&nbsp;1 or 2, with Grade&nbsp;3 pruritus occurring in 0.3% of patients. Nail disorders occurred in 56% of patients and were Grade&nbsp;1 or 2. See section 4.4 for management guidance.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>To report any side effects:</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:4.5pt;margin-top:20.7pt;
  width:451.5pt;height:25.5pt;z-index:251660288;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" o:allowincell="f" filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:0in;margin-bottom:
     0in;margin-left:.1in;margin-bottom:.0001pt;tab-stops:.35in;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><span lang=EN-GB
     style='font-size:11.5pt;color:black;mso-themecolor:text1;font-style:normal'>-<span
     style='mso-tab-count:1'>     </span>Please contact the relevant competent<span
     style='letter-spacing:-.3pt'> </span>authority.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="margin"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Other GCC States:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u></p><p>&nbsp;</p><p>The maximum tolerated dose of talquetamab has not been determined. In clinical studies, doses of up to 1.2&nbsp;mg/kg once every 2&nbsp;weeks and 1.6&nbsp;mg/kg every month have been administered.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>&nbsp;</p><p>In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment should be instituted immediately.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Monoclonal antibodies and antibody drug conjugates, ATC code: not yet assigned</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Talquetamab is a immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) bispecific antibody directed against GPRC5D and the CD3 receptor on T Cells.</p><p>&nbsp;</p><p>Talquetamab promotes enhanced T cell‑mediated cytotoxicity through recruitment of CD3‑expressing T cells to GPRC5D‑expressing cells. This leads to the activation of T cells and induces subsequent lysis of GPRC5D‑expressing cells mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T cells. Based on the expression of GPRC5D on plasma cells with minimal to no expression detected on B cells and B cell precursors, talquetamab targets multiple myeloma cells particularly.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>&nbsp;</em></p><p>Within the first month of treatment with talquetamab, activation and redistribution of T cells and induction of serum cytokines were observed.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>&nbsp;</em></p><p>The efficacy of TALVEY monotherapy was evaluated in patients with relapsed or refractory multiple myeloma in a single‑arm, open‑label, multicentre study, MonumenTAL‑1. The study included patients who had previously received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. The study excluded patients who received T cell redirection therapy within 3&nbsp;months, prior Grade&nbsp;3 or higher CRS related to any T cell redirection therapy, an allogenic stem cell transplant within the past 6&nbsp;months, autologous stem cell transplant within 3 months, stroke or seizure within the past 6&nbsp;months, CNS involvement or clinical signs of meningeal involvement of multiple myeloma, plasma cell leukaemia, active or documented history of autoimmune disease, with the exception of vitiligo, resolved childhood atopic dermatitis, POEMS syndrome, primary light chain amyloidosis and prior Grave&rsquo;s disease that was euthyroid based on clinical symptoms and laboratory testing.</p><p>Patients received TALVEY 0.4&nbsp;mg/kg subcutaneously weekly, following two step‑up doses (0.01 and 0.06&nbsp;mg/kg) in the first week of therapy, or TALVEY 0.8&nbsp;mg/kg subcutaneously biweekly (every 2&nbsp;weeks), following three step‑up doses (0.01, 0.06 and 0.3&nbsp;mg/kg), until disease progression or unacceptable toxicity. Patients were hospitalised for monitoring for at least 48&nbsp;hours after each TALVEY dose during the step‑up phase.</p><p>&nbsp;</p><p>Of 143&nbsp;patients treated with TALVEY 0.4&nbsp;mg/kg weekly who were not exposed to prior T cell redirection therapy, the median age was 67 (range: 46 to 86) years, 55% were male, 90% were White, and 8% were Black or African American. Patients had received a median of 5 (range: 2 to 13) prior therapies, and 78% of patients had received prior autologous stem cell transplantation (ASCT). Ninety‑four percent (94%) of patients were refractory to their last therapy, and 74% were refractory to a PI, immunomodulatory agent, and anti‑CD38 antibody. Of the 132&nbsp;patients for whom baseline cytogenetic data were available, high‑risk cytogenetic factors (presence of t(4:14), t(14:16), and/or del(17p)) were present in 31% of patients. Twenty‑three percent (23%) of patients had extramedullary plasmacytomas.</p><p>&nbsp;</p><p>Of 145&nbsp;patients treated with TALVEY 0.8&nbsp;mg/kg biweekly (every 2&nbsp;weeks) who were not exposed to prior T cell redirection therapy, the median age was 67 (range: 38 to 84) years, 57% were male, 86% were White, and 6% were Black or African American. Patients had received a median of 5 (range: 2 to 17) prior therapies, and 79% of patients had received prior autologous stem cell transplantation (ASCT). Ninety‑four percent (94%) of patients were refractory to their last therapy, and 69% were refractory to a proteasome inhibitor, immunomodulatory agent, and anti‑CD38 antibody. Of the 128&nbsp;patients for whom baseline cytogenetic data were available, high‑risk cytogenetic factors (presence of t(4:14), t(14:16), and/or del(17p)) were present in 29% of patients. Twenty‑six percent (26%) of patients had extramedullary plasmacytomas.</p><p>&nbsp;</p><p>Efficacy results were based on an overall response rate as determined by the Independent Review Committee assessment using IMWG criteria. The median duration of follow‑up among patients receiving TALVEY 0.4&nbsp;mg/kg weekly was 18.8&nbsp;months; an estimated 51.5% of responders maintained response for at least 9&nbsp;months.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results for MMY1001 (MonumenTAL‑1) in patients receiving TALVEY 0.4&nbsp;mg/kg weekly</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>0.4&nbsp;mg/kg weekly</strong><sup>a</sup></p><p><strong>(N=143)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response rate (ORR=sCR+CR+VGPR+PR) </strong></p></td><td style="vertical-align:top"><p>106 (74.1%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(66.1, 81.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Stringent complete response (sCR)</p></td><td style="vertical-align:top"><p>23.8%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Complete response (CR)</p></td><td style="vertical-align:top"><p>9.8%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very good partial response (VGPR)</p></td><td style="vertical-align:top"><p>25.9%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Partial response (PR)</p></td><td style="vertical-align:top"><p>14.7%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Duration of response (DOR)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>106</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median DOR (95% CI) (months)</p></td><td style="vertical-align:top"><p>9.5 (6.7, 13.3)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Time to first response </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>106</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (range) (months)</p></td><td style="vertical-align:top"><p>1.2 (0.2, 10.9)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MRD negativity rate<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>MRD negativity rate in all treated patients, n (%)</p></td><td colspan="2" style="vertical-align:top"><p>44 (30.8%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td colspan="2" style="vertical-align:top"><p>(23.3, 39.0)</p></td></tr><tr><td style="vertical-align:top"><p>MRD negativity rate<sup>b</sup> in patients achieving CR or sCR</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with CR or better</p></td><td colspan="2"><p>N=48</p></td></tr><tr><td style="vertical-align:top"><p>MRD negativity rate, n (%)</p></td><td colspan="2"><p>26 (54.2%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td colspan="2"><p>(39.2, 68.6)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI=confidence interval; MRD=minimal residual disease;</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; MRD‑negativity rate is defined as the proportion of participants who achieved MRD negative status (at 10<sup>-5</sup>) at any timepoint after initial dose and prior to progressive disease (PD) or subsequent anti‑myeloma therapy.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only MRD assessments (10<sup>-5</sup> testing threshold) within 3&nbsp;months of achieving CR/sCR until death/progression/subsequent therapy (exclusive) are considered.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The median duration of follow‑up among patients receiving TALVEY 0.8&nbsp;mg/kg biweekly was 12.7&nbsp;months; an estimated 76.3% of responders maintained response for at least 9&nbsp;months.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results for MMY1001 (MonumenTAL‑1) in patients receiving TALVEY 0.8&nbsp;mg/kg biweekly (every 2&nbsp;weeks)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>0.8&nbsp;mg/kg biweekly (every 2&nbsp;weeks)<sup>a</sup></strong></p><p><strong>(N=145)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Overall response rate (ORR=sCR+CR+VGPR+PR)</strong></p></td><td style="vertical-align:top"><p>104 (71.7%)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(63.7, 78.9)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Stringent complete response (sCR)</p></td><td style="vertical-align:top"><p>29.7%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Complete response (CR)</p></td><td style="vertical-align:top"><p>9.0%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Very good partial response (VGPR)</p></td><td style="vertical-align:top"><p>22.1%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Partial response (PR)</p></td><td style="vertical-align:top"><p>11.0%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Duration of response (DOR)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td colspan="3" style="vertical-align:top"><p>104</p></td></tr><tr><td style="vertical-align:top"><p>Median DOR (95% CI) (months)</p></td><td colspan="3" style="vertical-align:top"><p>NE (13.0, NE)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Time to first response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td colspan="3" style="vertical-align:top"><p>104</p></td></tr><tr><td style="vertical-align:top"><p>Median (range) (months)</p></td><td colspan="3" style="vertical-align:top"><p>1.3 (0.2, 9.2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>MRD negativity rate<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>MRD negativity rate in all treated patients, n (%)</p></td><td colspan="3" style="vertical-align:top"><p>43 (29.7%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td colspan="3" style="vertical-align:top"><p>(22.4, 37.8)</p></td></tr><tr><td style="vertical-align:top"><p>MRD negativity rate<sup>b</sup> in patients achieving CR or sCR</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with CR or better</p></td><td colspan="3"><p>N=56</p></td></tr><tr><td style="vertical-align:top"><p>MRD negativity rate, n (%)</p></td><td colspan="3"><p>24 (42.9%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td colspan="3"><p>(29.7, 56.8)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>CI=confidence interval; MRD=minimal residual disease; NE=not estimable</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MRD‑negativity rate is defined as the proportion of participants who achieved MRD negative status (at 10<sup>-5</sup>) at any timepoint after initial dose and prior to progressive disease (PD) or subsequent anti‑myeloma therapy.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only MRD assessments (10<sup>-5</sup> testing threshold) within 3 months of achieving CR/sCR until death/progression/subsequent therapy (exclusive) are considered.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>ORR results were consistent across pre‑specified subgroups, including number of prior lines of therapy, refractoriness to prior therapy, and cytogenetic risk at baseline.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>In MonumenTAL‑1, 328&nbsp;patients treated with subcutaneous talquetamab monotherapy at 0.4&nbsp;mg/kg weekly or 0.8&nbsp;mg/kg biweekly (every 2&nbsp;weeks), with or without prior T cell redirection therapy, were evaluated for antibodies to talquetamab. Following treatment 0.4&nbsp;mg/kg weekly or 0.8&nbsp;mg/kg biweekly (every 2&nbsp;weeks), 106 of 328&nbsp;patients (32.3%) developed anti‑talquetamab antibodies.</p><p>The limited number of anti‑talquetamab antibody (ADA) positive subjects and the lack of information of the neutralising ADA, preclude drawing a definite conclusion regarding the effect of the neutralising ADAs on clinical parameters.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with TALVEY in all subsets of the paediatric population in the treatment of multiple myeloma (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>0.4&nbsp;mg/kg weekly dose</u></p><p>&nbsp;</p><p>Talquetamab exhibited approximately dose‑proportional pharmacokinetics following subcutaneous administration across a dose ranging from 0.005 to 0.8&nbsp;mg/kg weekly (0.0125 to 2&nbsp;times the recommended 0.4&nbsp;mg/kg weekly dose). The mean accumulation ratio between the 1<sup>st</sup> and 7<sup>th</sup> weekly dose of talquetamab 0.4&nbsp;mg/kg was 3.9‑ and 4.5‑fold for C<sub>max</sub> and AUC<sub>tau</sub>, respectively.</p><p>&nbsp;</p><p>Pharmacokinetic parameters of talquetamab following the 1<sup>st</sup> and 7<sup>th</sup> recommended weekly dose of 0.4&nbsp;mg/kg are shown in Table&nbsp;10.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;10:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic parameters of talquetamab following the first and seventh recommended weekly dose (0.4&nbsp;mg/kg) in patients with relapsed or refractory multiple myeloma in MonumenTAL‑1</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Pharmacokinetic parameters</strong></p></td><td style="vertical-align:bottom"><p><strong>1<sup>st</sup> dose of 0.4&nbsp;mg/kg</strong></p></td><td style="vertical-align:bottom"><p><strong>7<sup>th</sup> dose of 0.4&nbsp;mg/kg</strong></p></td></tr><tr><td><p>T<sub>max</sub> (days)</p></td><td><p>2.93 (0.98 ‑ 7.75)</p><p>(n=21)</p></td><td><p>2.01 (0.94 ‑ 5.97)</p><p>(n=13)</p></td></tr><tr><td><p>C<sub>max</sub> (ng/mL)</p></td><td><p>1&nbsp;568&nbsp;&plusmn;&nbsp;1&nbsp;185</p><p>(n=21)</p></td><td><p>3&nbsp;799&nbsp;&plusmn;&nbsp;2&nbsp;411</p><p>(n=13)</p></td></tr><tr><td><p>C<sub>trough</sub> (ng/mL)</p></td><td><p>178&nbsp;&plusmn;&nbsp;124</p><p>(n=19)</p></td><td><p>2&nbsp;548&nbsp;&plusmn;&nbsp;1&nbsp;308</p><p>(n=13)</p></td></tr><tr><td><p>AUC<sub>tau </sub>(ng&middot;h/mL)</p></td><td><p>178&nbsp;101&nbsp;&plusmn;&nbsp;130&nbsp;802</p><p>(n=17)</p></td><td><p>607&nbsp;297&nbsp;&plusmn;&nbsp;371&nbsp;399</p><p>(n=10)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>T<sub>max </sub>= Time to reach the C<sub>max</sub>; C<sub>max </sub>= Maximum observed serum talquetamab concentration; C<sub>trough </sub>= Observed serum talquetamab concentration prior to next dose; AUC<sub>tau</sub> = Area under the concentration‑time curve over the weekly dosing interval. Data are presented as mean &plusmn; standard deviation, except for T<sub>max</sub> which is presented as median (minimum‑ maximum).</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>0.8&nbsp;mg/kg biweekly dose</u></p><p><u>&nbsp;</u></p><p>Talquetamab exhibited approximately dose‑proportional pharmacokinetics following subcutaneous administration across a dose ranging from 0.8&nbsp;mg/kg to 1.2&nbsp;mg/kg biweekly (1.0 to 1.5&nbsp;times the recommended 0.8&nbsp;mg/kg biweekly dose). The mean accumulation ratio between the 1<sup>st</sup> and 5<sup>th</sup> biweekly dose of talquetamab 0.8&nbsp;mg/kg was 2.3‑ and 2.2‑fold for C<sub>max</sub> and AUC<sub>tau</sub>, respectively.</p><p>&nbsp;</p><p>Pharmacokinetic parameters of talquetamab following the 1<sup>st</sup> and 5<sup>th</sup> recommended biweekly maintenance dose of 0.8&nbsp;mg/kg are shown in Table&nbsp;11.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;11:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic parameters of talquetamab following the first and fifth recommended biweekly (every 2&nbsp;weeks) dose (0.8&nbsp;mg/kg) in patients with relapsed or refractory multiple myeloma in MonumenTAL‑1</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Pharmacokinetic parameters</strong></p></td><td style="vertical-align:bottom"><p><strong>1<sup>st</sup> dose of 0.8&nbsp;mg/kg</strong></p></td><td style="vertical-align:bottom"><p><strong>5<sup>th</sup> dose of 0.8&nbsp;mg/kg</strong></p></td></tr><tr><td><p>T<sub>max</sub> (days)</p></td><td><p>2.83 (1.68 ‑ 13.98)</p><p>(n=33)</p></td><td><p>2.85 (0.96 ‑ 7.82)</p><p>(n=19)</p></td></tr><tr><td><p>C<sub>max</sub> (ng/mL)</p></td><td><p>2&nbsp;507&nbsp;&plusmn;&nbsp;1&nbsp;568</p><p>(n=33)</p></td><td><p>4&nbsp;161&nbsp;&plusmn;&nbsp;2&nbsp;021</p><p>(n=19)</p></td></tr><tr><td><p>C<sub>trough</sub> (ng/mL)</p></td><td><p>597&nbsp;&plusmn;&nbsp;437</p><p>(n=32)</p></td><td><p>1&nbsp;831&nbsp;&plusmn;&nbsp;841</p><p>(n=17)</p></td></tr><tr><td><p>AUC<sub>tau </sub>(ng&middot;h/mL)</p></td><td><p>675&nbsp;764&nbsp;&plusmn;&nbsp;399&nbsp;680</p><p>(n=28)</p></td><td><p>1&nbsp;021&nbsp;059&nbsp;&plusmn;&nbsp;383&nbsp;417</p><p>(n=17)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>T<sub>max </sub>= Time to reach the C<sub>max</sub>; C<sub>max </sub>= Maximum observed serum talquetamab concentration; C<sub>trough </sub>= Observed serum talquetamab concentration prior to next dose; AUC<sub>tau</sub> = Area under the concentration‑time curve over the Q2W dosing interval. Data are presented as mean &plusmn; standard deviation, except for T<sub>max</sub> which is presented as median (minimum‑maximum).</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Based on the population pharmacokinetic model, the typical value of the bioavailability of talquetamab was 62% when administered subcutaneously relative to intravenous dosing.</p><p>&nbsp;</p><p>At 0.4&nbsp;mg/kg weekly dose regimen, the median (range) T<sub>max</sub> of talquetamab after the 1<sup>st</sup> and 7<sup>th</sup> treatment doses were 3&nbsp;(1&nbsp;to&nbsp;8)&nbsp;days and 2&nbsp;(1&nbsp;to&nbsp;6)&nbsp;days, respectively.</p><p>&nbsp;</p><p>At 0.8&nbsp;mg/kg biweekly (every 2&nbsp;weeks) dose regimen, the median (range) T<sub>max</sub> of talquetamab after the 1<sup>st</sup> and 5<sup>th</sup> treatment doses were 3&nbsp;(2&nbsp;to&nbsp;14)&nbsp;days and 3&nbsp;(1&nbsp;to&nbsp;8)&nbsp;days, respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Based on the population pharmacokinetic model, the typical value of the volume of distribution was 4.3&nbsp;L (22% CV [coefficient of variation]) for the central compartment, and 5.8&nbsp;L (83% CV) for the peripheral compartment.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Talquetamab exhibited both linear time‑independent and time‑dependent clearance. Based on the population pharmacokinetic model and the post hoc parameters of participants receiving SC doses (N=392), the median total clearance is 1.64&nbsp;L/day at initial treatment and 0.80&nbsp;L/day at steady state. The time‑dependent clearance accounted for 48.8% of total clearance at initial treatment and then decreased exponentially to &lt;&nbsp;5% at around Week&nbsp;16. The concentration‑time profile at Week&nbsp;16 would reach 90% of steady‑state concentration for both 0.4&nbsp;mg/kg weekly and 0.8&nbsp;mg/kg biweekly regimens. The median terminal phase half‑life was 7.56&nbsp;days at initial treatment, and 12.2&nbsp;days at steady state.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p>The pharmacokinetic analysis includes 86 % White (n=424), 9% Black (n=43), 2.2% Asian (n=11), and 2.8% Others (n=14). Based on population PK analysis, the race or ethnicity, sex and body weight (range: 40 to 143&nbsp;kg) did not have clinically meaningful effects on the pharmacokinetics of talquetamab.</p><p><u>&nbsp;</u></p><p><em>Paediatric population </em></p><p>&nbsp;</p><p>The pharmacokinetics of TALVEY in paediatric patients aged 17&nbsp;years and younger have not been investigated.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>&nbsp;</p><p>Results of population pharmacokinetic analyses indicate that age (33 to 86&nbsp;years) did not influence the pharmacokinetics of talquetamab. Only limited data for patients &ge;&nbsp;85&nbsp;years was available (see Table&nbsp;12).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;12:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of elderly subjects in the pharmacokinetic (PK) studies of talquetamab</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Age 65‑74</strong></p><p><strong>(Older subjects number /total number)</strong></p></td><td style="vertical-align:top"><p><strong>Age 75‑84</strong></p><p><strong>(Older subjects number /total number)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Age 85+</strong></p><p><strong>(Older subjects number /total number)</strong></p></td></tr><tr><td style="vertical-align:top"><p>PK Studies</p></td><td style="vertical-align:top"><p>181/492</p></td><td style="vertical-align:top"><p>73/492</p></td><td colspan="2" style="vertical-align:top"><p>1/492</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>No formal studies of talquetamab in patients with renal impairment have been conducted.</p><p>Results of population pharmacokinetic analyses indicate that mild (60&nbsp;mL/min &le;&nbsp;absolute glomerular filtration rate (GFR) &lt;&nbsp;90&nbsp;mL/min) or moderate (30&nbsp;mL/min&nbsp;&le;&nbsp;absolute GFR&nbsp;&lt;&nbsp;60&nbsp;mL/min) renal impairment did not significantly influence the pharmacokinetics of talquetamab. No data is available in patients with severe renal impairment.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>&nbsp;</p><p>No formal studies of talquetamab in patients with hepatic impairment have been conducted.</p><p>Using the NCI classification, results of population pharmacokinetic analyses indicate that mild hepatic impairment (total bilirubin &gt;&nbsp;1 to 1.5&nbsp;times upper limit of normal (ULN) and any aspartate aminotransferase (AST), or total bilirubin &le;&nbsp;ULN and AST&nbsp;&gt;&nbsp;ULN) did not significantly influence the pharmacokinetics of talquetamab. Limited data (n=2) are available in participants with moderate hepatic impairment while no data are available in participants with severe hepatic impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A tool molecule was well tolerated in general toxicity studies in cynomolgus monkeys, but the results of these studies conducted with normal healthy monkeys have limited translatability to multiple myeloma patients.</p><p>&nbsp;</p><p><u>Carcinogenicity and mutagenicity</u></p><p>&nbsp;</p><p>No animal studies have been performed to assess the carcinogenic or genotoxic potential of talquetamab.</p><p>&nbsp;</p><p><u>Reproductive toxicology and fertility</u></p><p><u>&nbsp;</u></p><p>No animal studies have been conducted to evaluate the effects of talquetamab on reproduction and foetal development. No studies have been conducted to evaluate the effects of talquetamab on fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EDTA disodium salt dihydrate</p><p>Glacial acetic acid</p><p>Polysorbate 20</p><p>Sodium acetate trihydrate</p><p>Sucrose</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

18 months

Prepared syringe

Chemical and physical in use stability has been demonstrated up to 24 hours at 2 to 8°C followed by up to 24 hours at temperature of 15°C to 30°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless preparation has taken place in controlled and validated aseptic conditions. Discard if stored for more than 24 hours refrigerated or more than 24 hours of being at ambient temperature.

The prepared syringe should be stored protected from light.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after opening of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>TALVEY 2&nbsp;mg/mL solution for injection</u></p><p>1.5&nbsp;mL solution for injection in a Type&nbsp;1 glass vial with an elastomeric stopper and an aluminium seal with a light green flip‑off cap containing 3&nbsp;mg of talquetamab.</p><p>&nbsp;</p><p>Pack size of 1&nbsp;vial.</p><p>&nbsp;</p><p><u>TALVEY 40&nbsp;mg/mL solution for injection</u></p><p>1&nbsp;mL solution for injection in a Type&nbsp;1 glass vial with an elastomeric stopper and an aluminium seal with a violet flip‑off cap containing 40&nbsp;mg of talquetamab.</p><p>&nbsp;</p><p>Pack size of 1&nbsp;vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The TALVEY vials are supplied as ready‑to‑use solution for injection that do not need dilution prior to administration.</p><p>&nbsp;</p><p>TALVEY vials of different concentrations should not be combined to achieve treatment dose.</p><p>&nbsp;</p><p>Aseptic technique should be used to prepare and administer TALVEY.</p><p>&nbsp;</p><p><u>Preparation of TALVEY</u></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to the following reference tables for the preparation of TALVEY</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;13 to determine total dose, injection volume, and number of vials required based on patient&rsquo;s actual body weight for the 0.01&nbsp;mg/kg dose using TALVEY 2&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;13:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.01&nbsp;mg/kg dose: injection volumes using TALVEY 2&nbsp;mg/mL vial</strong></p></td></tr><tr><td rowspan="15"><p><strong>0.01&nbsp;mg/kg dose</strong></p></td><td style="vertical-align:top"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose<sup>a</sup></strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of injection (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial = 1.5&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35 to 39</p></td><td style="vertical-align:top"><p>0.38</p></td><td style="vertical-align:top"><p>0.19</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40 to 45</p></td><td style="vertical-align:top"><p>0.42</p></td><td style="vertical-align:top"><p>0.21</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>46 to 55</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0.25</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>56 to 65</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>66 to 75</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.35</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>76 to 85</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>86 to 95</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.45</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>96 to 105</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>106 to 115</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.55</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>116 to 125</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>126 to 135</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.65</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>136 to 145</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>146 to 155</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.75</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>156 to 160</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Total dose (mg) is calculated based on the rounded Volume of injection (mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;14 to determine total dose, injection volume, and number of vials required based on patient&rsquo;s actual body weight for the 0.06&nbsp;mg/kg dose using TALVEY 2&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;14:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.06&nbsp;mg/kg dose: injection volumes using TALVEY 2&nbsp;mg/mL vial</strong></p></td></tr><tr><td rowspan="15"><p><strong>0.06&nbsp;mg/kg dose</strong></p></td><td style="vertical-align:top"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose<sup>a</sup></strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of injection (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial = 1.5&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35 to 39</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40 to 45</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>46 to 55</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>56 to 65</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>66 to 75</p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>76 to 85</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>86 to 95</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>96 to 105</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>106 to 115</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>116 to 125</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>126 to135</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>136 to145</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>146 to155</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>156 to160</p></td><td style="vertical-align:top"><p>9.6</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; The Total dose (mg) is calculated based on the rounded Volume of injection (mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;15 to determine total dose, injection volume and number of vials required based on patient&rsquo;s actual body weight for the 0.4&nbsp;mg/kg dose using TALVEY 40&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;15:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4&nbsp;mg/kg dose: injection volumes using TALVEY 40&nbsp;mg/mL vial</strong></p></td></tr><tr><td rowspan="15"><p><strong>0.4&nbsp;mg/kg dose</strong></p></td><td style="vertical-align:top"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose<sup>a</sup></strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of injection (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial = 1.0&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35 to 39</p></td><td style="vertical-align:top"><p>14.8</p></td><td style="vertical-align:top"><p>0.37</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40 to 45</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>46 to 55</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>56 to 65</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>66 to 75</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>76 to 85</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>86 to 95</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>96 to 105</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>106 to 115</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>116 to 125</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>126 to 135</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>136 to 145</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>146 to 155</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>156 to 160</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; The Total dose (mg) is calculated based on the rounded Volume of injection (mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;16 to determine total dose, injection volume, and number of vials required based on patient&rsquo;s actual body weight for the 0.8&nbsp;mg/kg dose using TALVEY 40&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;16:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.8&nbsp;mg/kg dose: injection volumes using TALVEY 40&nbsp;mg/mL vial</strong></p></td></tr><tr><td rowspan="15"><p><strong>0.8&nbsp;mg/kg dose</strong></p></td><td style="vertical-align:top"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose<sup>a</sup></strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of injection (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial = 1.0&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35 to 39</p></td><td style="vertical-align:top"><p>29.6</p></td><td style="vertical-align:top"><p>0.74</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40 to 45</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0.85</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>46 to 55</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>56 to 65</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>66 to 75</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>76 to 85</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>86 to 95</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>96 to 105</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>106 to 115</p></td><td style="vertical-align:top"><p>88</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>116 to 125</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>126 to 135</p></td><td style="vertical-align:top"><p>104</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>136 to 145</p></td><td style="vertical-align:top"><p>112</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>146 to 155</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>156 to 160</p></td><td style="vertical-align:top"><p>128</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; The Total dose (mg) is calculated based on the rounded Volume of injection (mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check that the TALVEY solution for injection is colourless to light yellow. Do not use if the solution is discoloured, cloudy, or if foreign particles are present.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the appropriate strength TALVEY vial from refrigerated storage (2&deg;C to 8&deg;C) and equilibrate to ambient temperature (15&deg;C to 30&deg;C) for at least 15&nbsp;minutes. Do not warm TALVEY vial in any other way.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once equilibrated, gently swirl the vial for approximately 10&nbsp;seconds to mix. Do not shake.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required injection volume of TALVEY from the vial(s) into an appropriately sized syringe using a transfer needle.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each injection volume should not exceed 2.0&nbsp;mL. Divide doses requiring greater than 2.0&nbsp;mL equally into multiple syringes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TALVEY is compatible with stainless steel injection needles and polypropylene or polycarbonate syringe material.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the transfer needle with an appropriately sized needle for injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the prepared syringe is stored in the refrigerator, allow the solution to come to ambient temperature before administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag International NV
Turnhoutseweg 30
B 2340 Beerse
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>